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Abstract
This study investigated differences in outcomes related to health, swallowing, and
quality of life (QoL) for individuals with oropharyngeal squamous cell carcinoma (OPSCC)
receiving either radiotherapy (RT) alone, or concomitant chemoradiotherapy (CRT). Differences
were assessed based on whether patients received a feeding tube (FT group) or not (NFT
group). Measures including the Functional Oral Intake Scale (FOIS), Performance Status Scale
for Head and Neck Cancer (PSS-HN), M.D. Anderson Dysphagia Inventory (MDADI), and weight
were collected for 126 individuals at baseline, and at 3, 6, and 12 months post-treatment. Data
were analyzed to identify potential prognostic differences between the groups, and to assess
pre-treatment differences which may have led to the need for and dependence on enteral
feeding. Within-group analyses were also performed to determine the trajectory of recovery for
both groups. In general, the most notable differences were found at 3 months, with the NFT
group performing significantly better in outcomes related to functional oral intake and
swallowing-related QoL. However, patients in the NFT group were more likely to have clinically
significant decreases in weight, even at 12 months, showing difficulty with recovering back to
baseline status. Although the results of this retrospective chart review are preliminary, the
findings have the potential to contribute to improved decision-making and communication in a
clinical setting, and may ultimately lead to better outcomes for those with OPSCC.
Keywords: oropharyngeal cancer, radiotherapy, chemoradiotherapy, enteral feeding,
swallowing, dysphagia, oral intake, quality of life
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Chapter 1: Introduction and Review of Literature
Overview
To achieve favourable post-treatment outcomes, individuals diagnosed with head and
neck cancer (HNC) are often prescribed aggressive forms of treatment, including surgery,
radiotherapy (RT) and/or chemotherapy – alone or in combination (Guru, Manoor, & Supe,
2012). Despite being effective at treating HNC, and often successful in preserving organ
structure, issues related to organ function are commonly experienced by patients/survivors
(Shaw et al., 2015). Treatment-induced complications such as dysphagia (difficulty or
discomfort in swallowing), oral mucositis (erythematous and ulcerative lesions of the oral
mucosa), fatigue, xerostomia (subjective complaint of dry mouth), dermatitis (inflammation of
the skin) and pain significantly impact the quality of life (QoL) and well-being of survivors
(Manoor et al., 2012). Moreover, due to the unique anatomic location of the tumour itself (in
the head and neck region) and the resultant impairments, difficulty and pain with oral intake is
often experienced. As a result, the patient’s ability to obtain the nutrition necessary to meet
energy requirements and effectively undergo treatment is compromised, subsequently
increasing the risk of weight loss (Shaw et al., 2015).
Current literature suggests that one marker of successful patient-centred treatment of
HNC is the prevention of weight loss (Languis et al., 2016; Shaw et al., 2015; Bhayani et al.,
2013), emphasizing the importance of nutritional management for this clinical oncology
population. Consequently, physicians routinely utilize enteral feeding for nutritional support
when oral intake is insufficient or inadequate (Lees, 1997; Magne et al., 2001). Enteral feeding
tubes, such as a percutaneous endoscopic gastrostomy (PEG) tube, provide an alternative

2

method for patients to obtain adequate nutrition. Eating by mouth might be restricted due to
treatment-related issues, such as pain, but also general fatigue. Patients often eat less because
of pain, changes in taste, and altered energy levels. Severe treatment-related dysphagia can
encompass a variety of issues such as poor mobility of the swallowing mechanism, altered
sensation, increased risk of choking, and chronic aspiration, which also can lead to an overall
reduced ability to sustain an oral diet (Nguyen et al., 2006).
Instead of relying on oral consumption of food/liquids, which may become more difficult
and painful over the course of treatment, feeding tubes allow for more direct access to the
gastrointestinal tract, such as into the stomach (enteral route), in cases where the tube has
been inserted through the wall of the abdomen (Paleri & Patterson, 2010). Because this
method allows patients to bypass the mouth and upper aerodigestive tract while meeting
nutritional needs, pain associated with treatment-related toxicities is avoided, in turn allowing
patients to receive adequate nutrition despite impaired swallowing function (Paleri &
Patterson, 2010). As a result, it is believed that the risk of weight loss and malnutrition often
experienced during treatment can be minimized or avoided altogether (Brown et al., 2015).
Despite the abundant literature demonstrating the impact of differing methods of
enteral feeding, such as prophylactic versus reactive placement approaches (to be addressed in
full later on in the paper) on weight loss and other swallowing-related health outcomes, little
attention has been placed on determining the impact of feeding tube status on specific
outcome measures. This includes variables such as the Functional Oral Intake Scale (FOIS), the
M.D. Anderson Dysphagia Inventory (MDADI), the Performance Status Scale for Head and Neck
Cancer (PSS-HN), weight, and feeding tube duration. At present the use of enteral feeding tubes
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differs across institutions, and even across health care professionals within institutions. Paired
with the fact that patients are encouraged to consume food by mouth even if they receive a
feeding tube (Bhayani et al., 2013; Hutcheson et al., 2013), discrepancies in usage may be
present despite the same method being utilized. As such, documenting feeding tube status and
investigating the impact it has on these specific health outcomes may provide valuable
information regarding the impact of feeding tube use on swallowing function and QoL of
patients.
Due to the complex nature of treatment and the variety of ways in which treatment may
be prescribed, it is important to not only investigate the differences between groups of patients
who have received a tube or not, but to also consider how each group changes over time during
the course of treatment with respect to the outcome variables of interest. In addition,
examining how patients respond to treatment depending on their feeding tube status, rather
than simply focusing on method of administration (prophylactic vs. reactive), will provide
insight into the potential advantages and disadvantages of administering a feeding tube.
Furthermore, determining the impact of feeding tube status on factors such as oral intake and
QoL and investigating how they change during/after treatment offers a strategic advantage. By
doing so, physicians may be able to better communicate with patients and set goals based on
what amount of oral intake would be ideal depending on whether or not they have a feeding
tube in place. It also establishes a sort of benchmark, indicating at what level/measure a patient
should be at a specific point in time depending on whether or not they have a feeding tube in
place.
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Head and Neck Cancer
Head and neck cancer (HNC) is a broad disease term encompassing epithelial
malignancies arising in the oral cavity, paranasal sinuses, nasal cavity, pharynx and larynx
(Canadian Cancer Statistics, 2015). HNC is currently the 13th most common type of cancer in
Canada, affecting roughly 36,000 new Canadians each year (Forte, Niu, Lockwood, & Bryant,
2012). Worldwide, HNC is the fifth most common type of cancer with the seventh highest
cancer mortality (Guru, Manoor, & Supe, 2012). This translates into greater than 500,000 new
cases per year worldwide, adding to a global prevalence of 900,000 diagnosed individuals (Shaw
et al., 2015). Most of the epithelial malignancies falling under the umbrella term HNC are
squamous cell carcinoma of the head and neck (SCCHN; Argiris, Karamouzis, Raben, & Ferris,
2008). Squamous cells are found in mucous membranes (moist tissue lining cavities like the
blood vessels, lungs, intestines and airways), allowing for necessary bodily processes to be
carried out efficiently (Argiris et al., 2008). About 66% of patients diagnosed with SCCHN have
advanced stage disease, often involving local lymph nodes. Nevertheless, distant metastasis
upon initial presentation is uncommon, occurring in only 10% of patients (Ries et al, 2007).
The complexity of this disease is emphasized by its heterogeneous nature, with variation
(with regards to risk factors, diagnosis and treatment) being present across different anatomic
sub-sites. The oral cavity, representing the uppermost part of the digestive tract, starts at the
lips and ends at the anterior surface of the faucial arch (Omura, 2014). Necessary for functions
such as mastication, swallowing, and speech, the mucosal aspect of the oral cavity can be
divided in to five main sites: the tongue, the floor of the mouth, maxillary/mandibular gingiva,
buccal mucose, and hard plate (Omura, 2014). Currently, oral cancer is the sixth most common
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cancer worldwide, and is primarily treated according to the disease stage. Still, the main
treatment modality for this disease remains to be surgery, offering the distinct advantage of
adequate tumour tissue clearance and in turn decreasing the risk of local/regional recurrence,
and increasing long-term survival rates (Omura, 2014).
The oropharynx is often described as the region of the pharynx immediately posterior to
the oral cavity, including the palatine tonsils, base of tongue, lateral walls of the pharynx, and
posterior pharyngeal wall (Sasegbon & Hamdy, 2016; National Cancer Institute, 2002). While
there are various types (e.g., salivary gland carcinomas and lymphomas of Waldeyer’s ring),
oropharyngeal squamous cell carcinoma (OPSCC) makes up over 95% of oropharyngeal cancers
(van Monsjou, Balm, van den Brekel, & Wreesmann, 2010). For most OPSCCs, the standard of
care is RT, with or without chemotherapy (Bhayani et al., 2013)
The larynx, positioned between the base of the tongue and trachea, contains the vocal
cords and is responsible for producing phonation. In addition, the larynx is also functions to
protect the airway, and to regulate intra-thoracic and intra-abdominal pressure (Sasaki &
Isaacson, 1988). Early stage laryngeal cancer is often treated using radiation therapy or
transoral laser excision, while treatment of locally advanced laryngeal cancer favours a surgical
approach, often requiring a total laryngectomy (Licitra et al., 2003; Tomeh & Holsinger, 2014).
However, since performing laryngectomy is associated with poor health outcomes for patients
(Daly et al., 2010), non-surgical, organ preserving treatments have been thoroughly
investigated. Literature suggests that combining chemotherapy and RT for advanced carcinoma
of the larynx provides similar results when compared to surgical treatment options (Wolf et al.,
1991; Forastiere et al., 2003; Featherstone et al., 2004).
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Risk factors associated with the development of HNC cancer are well-established, with
the most significant being tobacco and alcohol abuse, as well as poor oral hygiene (Vineis et al.,
2004). In fact, combined abuse of tobacco and alcohol has been demonstrated to lead to a
three to six-fold increase in risk for the development of a malignant tumour of the tongue or
oral mucosa (Wermker et al., 2011). Furthermore, the two risky behaviours are implicated in
about 75% of all HNC, and when used in combination have an amplified effect (Vineis et al.,
2004; Blot et al., 1988; Tuyns et al., 1988). In addition to placing individuals at a higher risk for
HNC, these risk factors are often associated with poor nutrition and a reduced body mass index
(BMI). This further contributes to difficulty with nutrition and weight management, which are
recognized as important variables associated with successful treatment and recovery (Vineis et
al., 2004). Not only does treatment vary based on the sub-site, but data also suggest that risk
based on alcohol and tobacco use also differs according to the carcinoma location (Bhayani et
al., 2013). Laryngeal cancer has a strong correlation with the use of tobacco, whereas alcohol
use has been shown to have a strong correlation with an increased risk for oral and
oropharyngeal cancer (Hashibe et al., 2009; Lubin et al., 2009; Purdue et al., 2008). Despite a
decrease in risky behaviours such as smoking, oropharyngeal cancer incidence has been on the
rise (Bhayani, 2013).
Conventionally, OPSCC is categorized as SCCHN, and grouped together with squamous
cell carcinomas of all other sub-sites. While this may be useful based on the commonality
shared between cancers of squamous cells, OPSCC is unique due to its etiological, biological and
epidemiological characteristics (van Monsjou et al., 2010). The rise in incidence of OPSCC has
been attributed to human oncogenic papillomavirus virus (HPV), as it has been found in 77% of
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all patients with oropharyngeal cancer (De Stefani et al., 2013). Although the increased
incidence of oropharyngeal cancer is concerning, improved survival outcomes are often seen
with these patients compared to those with HNC not caused by HPV (Gillison et al., 2000; Ang
et al., 2010; Chung & Gillison, 2009; Jemal et al., 2004). As a result, an HPV positive diagnosis is
favourable for prognosis in patients with SCCHN. Tumours positive for HPV have been shown to
respond better to chemoradiotherapy (CRT) treatment, and may be more prone to immune
surveillance of tumour-specific antigens when compared to HPV-negative tumours (Argiris et
al., 2008). Therefore, the HPV status of a HNC patient may serve as an important predictive
biomarker, and is now taken into consideration during treatment. Because of the unique
etiologic association between HPV and OPSCC, treating patients with OPSCC will differ based on
whether or not the virus is present, as well as what structures of the oropharynx are involved.
Cancer of the Oropharynx
Cancer of the oropharynx, as well as the treatment used to eradicate the disease has the
potential to impede several vital functions. The oropharynx, which includes the soft palate,
base of the tongue, side and back of the throat, and tonsils (National Cancer Institute, 2002), is
one component of the pharynx, a hollow tube-like structure through which food and air pass on
their way to the esophagus or trachea, respectively (National Cancer Institute, 2002).
Therefore, it is clear that cancers arising in this region would negatively impact an individual’s
ability to eat and drink, considering the anatomical location of the involved structures. Out of
the involved structures, the tonsils are most commonly the site of oropharyngeal cancer,
followed by base of tongue cancer (Licitra et al., 2002).
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OPSCC makes up the vast majority of oropharyngeal cancers and in general has survival
rates comparable to that of SCCHN. When diagnosed with OPSCC, it has been suggested that
individuals have a 5-year survival rate of approximately 66% (Howlader et al., 2014).
Oropharyngeal tumours, especially those that arise at the base of the tongue, are often more
advanced when diagnosed, and are also more likely to have spread locally to adjacent lymph
nodes. Tumours are often larger (i.e., more advanced), with evidence of local spread of disease
by early detection made difficult since small tumours cause little discomfort and/or pain,
ultimately going unnoticed (Ramqvist & Dalianis, 2010). Moreover, even when oropharyngeal
tumours are at a similar stage, have comparable histologic features, and standardized
treatment (often involving CRT) is used, predicting functional outcomes is difficult. A late
diagnosis may also relate to the fact that initial symptoms of oropharyngeal cancer are often
attributed to the presence of chronic inflammatory disease of the pharynx mucosa (Licitra et
al., 2002). For this reason, establishing predictive/prognostic indicators would be clinically
valuable in terms of prevention and treatment for OPSCC (Ramqvist & Dalianis, 2010).
Treatment of OPSCC
Surgical options. With a demographic shift to a much younger population (related to
the increase in HPV-associated OPSCC) that is usually high functioning and absent of comorbid
illnesses, in combination with higher overall and disease-free survival rates, approaches
concerned with the preservation of organs and functioning and have become even more
relevant (Nasman et al., 2009). As such, open surgery has fallen out of favour, but transoral
surgical approaches are now associated with promising results. The use of transoral robotic
surgery (TORS) has demonstrated the ability to positively improve post-treatment functioning
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and QoL for individuals diagnosed with OPSCC (Dowthwaite et al., 2012) and for some patients,
this may be the treatment of choice.
Radiation therapy treatment. Radiation therapy is routinely used in the treatment of
HNC. For many early stage cancers, RT may be the only treatment necessary (Guru, Manoor, &
Super, 2012). Organ-sparing treatments (i.e., treatments that do not involve removal of
complete structures), such as RT and chemotherapy, are often successful at treating HNC and
are able to preserve tissue structure without compromising patient survival outcomes (Shaw et
al., 2015). Previously, 3D-conformal RT was used to achieve such results (Marta et al., 2013).
Technological advancements in radiation therapy techniques have also yielded improvements
in the capacity of treatment to deliver radiation effectively to the tumour while minimizing
irradiation of normal tissues surrounding the target (Sheets et al., 2014). Since many tissues in
close proximity to the area being treated with radiation therapy are at risk, contouring around
and avoiding these areas has been vital in maintaining function post-treatment (Sun et al.,
2013).
The emergence of new techniques has led to the development of intensity-modulated
radiotherapy (IMRT), an advanced form of 3D-conformal RT which uses non-uniform radiation
intensities to achieve a higher dose-delivery to the tumour, while simultaneously limiting the
radiation dose directed to surrounding tissues (Sheets et al., 2014; Marta et al., 2013). Sparing
adjacent tissues (e.g., salivary tissues) from the toxic effects of radiation will allow for improved
rehabilitation while minimizing associated adverse effects from treatment. IMRT offers several
advantages over conventional RT treatment including a reduction in side effects (especially
xerostomia), as well as reduced damage to the parotid gland, preserved salivary flow, and
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improved quality of life for patients (Sheets et al., 2014; Marta et al., 2013). Since maintaining
nutritional status is crucial for successful treatment (i.e., ridding the body of the tumour while
minimizing toxicities and maintaining a high QoL post-treatment), reducing the severity of side
effects such as dysphagia and xerostomia may allow patients to eat/drink more comfortably,
resulting in improved weight control, nutritional status, and overall allow for patients to be less
effected by treatment in a negative manner. Accordingly, IMRT has been adopted as the
primary treatment modality in clinical settings (Marta et al., 2013).
Concomitant/concurrent chemoradiotherapy. Treatment of HNC is often further
intensified by the addition of a chemotherapy regimen. As a result of the unacceptably low
survival rate of this patient population (Lasrado et al., 2014), the feasibility and impact of
concomitant/concurrent CRT (instead of RT alone, or one followed by the other) has been
extensively researched. Concomitant CRT is an alternative, combined modality treatment
option for HNC patients, involving the use of chemotherapy drugs in addition to RT (Bernier &
Cooper, 2004). Different classes of agents, including platinum compounds, antimetabolites, and
taxanes have demonstrated effectiveness in treating SCCHN (Covelas, 2006). Cisplatin, a
chemotherapeutic platinum-based compound, is currently regarded as a standard agent used in
combination with radiation therapy.
Another common platinum-based compound used in chemotherapy regimens is
carboplatin, which is typically well tolerated but less active (thus may take more treatments to
administer) than cisplatin (De Andres et al., 1995; Forastierre et al., 1992) despite their similar
radiosensitizing (the ability to make tumour cells more sensitive to RT) capabilities (Jeremic et
al., 1997). Additionally, agents involved in the suppression of epidermal growth factor receptor
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(EGFR) such as cetuximab are becoming more widely used for CRT (Karamouzis, Grandis, &
Argiris, 2007). The ability of such agents to supress this receptor, which is responsible for many
critical cellular functions in epithelial malignancies and whose expression is detected in more
than 90% of SCCHN patients, allows for improved locoregional control. Magrini et al. (2016)
found that hematologic, renal, and GI toxicities were more frequently observed in patients
treated with concomitant cisplatin compared to those treated with concomitant cetuximab. On
the contrary, cutaneous toxicity and the need for nutritional support were discovered to be
significantly more frequent in the group receiving concomitant cetuximab treatment. Factors
such as patterns of failure, locoregional control, and survival were similar between the two
groups of patients (Magrini et al., 2016). All of the listed compounds are commonly used in CRT
treatment, and are likely to form part of the treatment received by participants in this research
investigation.
In spite of the advantages and apparent superiority of CRT as a treatment modality as
demonstrated in a number of large randomized controlled trials (Adelstein et al., 2003; Brizel et
al., 1998; Budach et al., 2005), the use of CRT has also been associated with increased
treatment-related toxicities (Adelstein et al., 2003; Brizel et al., 1998; Aquilar-Ponce et al.,
2013; Vokes et al., 2000; Moroney et al., 2017). In fact, patients receiving IMRT alone
experience a lower incidence of adverse events and symptoms compared to those receiving
CRT, with CRT patients having at least twice the risk of experiencing most symptoms (Moroney
et al., 2017). The increase in adverse events such as dysphagia, mucositis (oral and pharyngeal),
xerostomia, nausea, and radiodermititis can lead to even more difficulty in nutritional
management for HNC patients because of their negative impact on the structure and

12

functioning of the head and neck (Moroney et al., 2017). These issues make eating and drinking
even more painful and difficult than when RT is used alone, emphasizing the importance of
proper nutrition throughout treatment, which is especially important for this patient
population. However, because of high locoregional control (Al-Sarraf et al., 1997; Vokes et al,
2000; Bernier & Cooper, 2004), increased survival rates with organ preservation (Bonner et al.,
2004; Vokes et al., 2000, Bernier & Cooper, 2004) and the capability to reverse a historical
pattern of failure with more traditional, monothereaputic treatments (Vokes et al., 2000), CRT
is commonly used in modern clinical practice and thus will be the main treatment modality
utilized by physicians in this research study.
OPSCC is cured at a relatively high rate, especially in cases of HPV-positive tumours (Ang
et al., 2010). Not only do patients have relatively normal functioning and performance at
baseline, but they are also living longer after completing treatment (Jang et al., 2013).
Accordingly, treatment-related toxicities should play a key role in determining treatment
strategy. Due to the prolonged life expectancy, coupled with the common need for enteral
feeding, emphasis should be placed on minimizing the toxic effects of treatment (such as
dysphagia and mucositis) as well as lowering the risk of becoming dependent on enteral
feeding. These concerns raise numerous questions specific to how treatment-related side
effects influence outcomes, particularly in association with feeding and nutritional status during
and following treatment.
Critical to the improved survival outcomes are the treatments used for oropharyngeal
cancer patients. New treatment advances are centred on de-escalation as a way to improve
function post treatment, and in turn lead to improved health outcomes and QoL despite the
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rise in incidence of oropharyngeal cancer. Research has shown that RT in combination with
chemotherapy is ideal in improving locoregional control, organ preservation, and improved
survival for these patients. For many centres, the standard of care for OPSCC for the last couple
of decades has been CRT; in light of TORS, treatment paradigms may shift in the future.
Swallowing and Treatment-Related Side Effects
Even though treatment has become more effective and less toxic for patients, CRT still
has the unfortunate consequence of damaging healthy cells, and in turn, causing severe side
effects. More specifically, CRT has broad ranging effects on muscle and connective tissue,
mucosa, and salivary glands, and changes to any these structures may result in functional
consequences/impairments, negatively affecting patients’ health and QoL. These areas, along
with the physiology and role of swallowing, will be presented briefly in the sections to follow.
Physiology of swallowing. Swallowing is a vital process necessary for survival and the
enablement of life. Requiring the use of more than 30 muscles and nerves, and including the
use of both volitional and reflexive behaviours, eating and swallowing are complex actions that
allow for food and fluids to be ingested in a safe and efficient manner (Matsuo & Palmer, 2009).
By doing so, the regular physiological and biochemical processes are maintained (Sasegbon &
Hamdy, 2016). The physiology behind this multifaceted process is often described using the
Four Stage Model, which includes the oral preparatory, oral propulsive, pharyngeal, and
esophageal stages of swallowing (Matsuo & Palmer, 2009). In order to compensate for the
inability of the Four Stage Model to describe the movement of the bolus and the process of
eating solid food, the Process Model of Feeding was established (Palmer, Rudin, Lara, &
Crompton, 1992; Dua, Ren, Bardan, Xie, & Shaker, 1997; Hiiemae & Palmer, 1999). This model
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takes into account the formation of a bolus in the oropharynx several seconds preceding the
pharyngeal stage and the passage and accumulation of portions of food in the oropharynx while
food remains in the oral cavity during chewing. Together, these models encompass the whole
swallowing mechanism and the passage of food from the mouth to the stomach. Issues are
experienced at any point along the swallowing pathway may lead to dysphagia (Sasegbon &
Hamdy, 2016).
For food and/or liquid to be safely consumed and subsequently digested as a means of
obtaining nutrition, the swallowing process must go through stages according to the models
described above. Consequences resulting due to difficulty with swallowing (dysphagia) can
present themselves in various ways. One unfortunate consequence is aspiration, described as
coughing or choking as a result of food entering into the trachea/windpipe through the larynx.
Aspiration, if it occurs during the treatment of HNC in combination with neutropenia (deficiency
in neutrophils predisposing patients to bacterial infection; Boxer & Dale, 2002), may lead to
aspiration pneumonia, sepsis, and respiratory failure (Lakshmaiah et al., 2013). Avoiding
aspiration is essential for the bolus to safely pass into the pharynx. Fortunately, built into the
swallowing process are several mechanisms designed to protect against aspiration of materials
into the trachea (Matsuo & Palmer, 2009). One way in which the trachea is protected during
swallowing is by the closure of the larynx at various levels (Lundy et al., 1999). Closure of the
vocal folds occurs to seal the glottis, with the arytenoids tilting anteriorly, contracting the base
of the epiglottis prior to the opening of the upper esophageal sphincter (Matsuo & Palmer,
2009). Additionally, the epiglottis tilts back to cover the laryngeal opening, and the larynx and
hyoid are pulled anteriorly and superiorly by the contraction of the suprahyoid and thyrohyoid
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muscles, effectively removing the larynx from the path of the bolus (Lundy et al., 1999; Matsuo
& Palmer, 2008). In essence, the larynx is displaced and tucked under the base of the tongue,
preventing food and liquid from entering and moving further into the trachea. Improper
coordination/timing of events which occur either prior to, during, or after the pharyngeal stage
of swallowing, can also lead to aspiration despite the above-mentioned laryngeal mechanisms
still being intact (Lundy et al., 1999).
In addition to protecting the airway to avoid an unsafe swallow and the potential
consequences (i.e., aspiration and pneumonia), swallowing also facilitates efficient bolus flow
to support nutrition and hydration (Sasegbon & Hamdy, 2016). When the bolus is transported
from the oral cavity to the oropharynx, the pharyngeal response is initiated as well. A series of
motor actions are subsequently activated, including the elevation of the soft palate, retraction
of the tongue base, closure of the larynx and contraction of the pharynx. All of the actions listed
above are required for efficient transport of the bolus into the esophagus (Lundy et al., 1999).
This explains why damage to the aforementioned structures (via CRT or surgical resection) will
exhibit the greatest impact on swallowing (Mittal et al., 2003; Brggreven et al., 2007). By
ensuring sufficient food and liquid pass through the system to be absorbed, swallowing plays a
major supportive role in obtaining required nutrients.
Many HNC patients receive a tube to keep them nourished, rather than to avoid unsafe
swallowing (although this may be the case for some patients who may develop difficulty with
closing off the airway). The supportive role of swallowing, often impaired due to treatmentrelated toxicities, is then taken on by the feeding tube. In summary, humans must swallow in
order to protect the airway (preventing aspiration and possible pneumonia) and to get

16

sufficient food and liquid through the system, in turn supporting nutrition and hydration.
Difficulty with swallowing (dysphagia) can affect this process and make it far more difficult to
obtain nutrition and to maintain weight, which is especially concerning during CRT treatment.
As well as being important for eating and allowing adequate nutrition and hydration to be
obtained, swallowing has a part in the enjoyment of eating, which plays an important role in
one’s perception of their QoL (Sasegbon & Hamdy, 2016). Since eating and drinking can be
enjoyable and positively affect one’s QoL (Ney et al., 2010; Eslick & Talley, 2008), any
impairment affecting the swallowing process has the potential to negatively impact QoL.
Musculature and connective tissue. A common yet serious and potentially dangerous
complication resulting from HNC treatment and its damaging effects on human musculature
and connective tissue is dysphagia (Nguyen et al., 2006). Dysphagia can be described as
difficulty or discomfort in swallowing, often leading to malnutrition, dehydration, significant
morbidity, increased mortality and decreased QoL (Langendijk et al., 2008; Nguyen et al., 2005).
There are various diseases that have the potential to disrupt regular swallowing, thereby
resulting in dysphagia (Sasegbon & Hamdy, 2016). In this case however, it is not the disease
itself (although a tumour in the head and neck may be disruptive to the swallowing process if
obstructive enough) causing dysphagia. It is the unwanted side-effects from treating the cancer
affecting the musculature and connective tissues in the head and neck affecting the individual’s
ability to swallow. These harmful changes impact the patient’s ability to eat by mouth, with
potential to cause malnutrition, dehydration and aspiration pneumonia, leading to significant
mortality and morbidity (Jaradeh, 1994).
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The toxic effects experienced by patients receiving CRT are especially influential on the
structure and function of the pharyngeal constrictor muscles. In spite of the numerous ways to
measure dysphagia in HNC patients, including duration of feeding tube use, stricture,
aspiration, videofluoroscopy, and physician/patient reported toxicity, the majority of research
on the topic indicates that treatment-induced damage to the pharyngeal constrictor muscles is
a main contributor to persistent and late dysphagia (Vlacich et al., 2013; Duprez, Madani, De
Potter, Boterberg, & De Neve, 2013). Vlachic et al. also reported that only dose to the inferior
pharyngeal constrictor muscle was associated with length of feeding tube dependency, further
emphasizing the link between structure and function related to oral nutrition. The link between
damage to pharyngeal constrictor muscles and treatment-induced complications (e.g.
dysphagia, mucositis, etc.) is evident, indicating that healthy constrictor muscles are necessary
to ensure proper swallowing function. Functioning of the constrictor muscles as a swallowingrelated health outcome is valuable because of its association with feeding tube dependence
and severe dysphagia (Shaw et al., 2015). In addition, functioning of the constrictor muscles is
an objective measure of dysphagia, which is in turn significantly associated with patient
morbidity (Shaw et al., 2015).
One of the most common and often debilitating consequences of cancer and its
treatment is pain, especially with swallowing. Pain associated with swallowing is referred to as
odynophagia, and along with dysphagia is quite common in HNC patients. Despite substantial
improvements in the treatment of OPSCC, pain is still frequently experienced by patients
(McMenamin & Grant, 2015). The tumour itself may be responsible for causing pain, potentially
compressing blood vessels and/or nerves. Moreover, because CRT treatment is not yet able to
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specifically target cancer cells, normal cells in close proximity to the cancerous ones are often
damaged, causing many side-effects and pain (Epstein et al., 2010).
Increased pain may lead to subsequent issues including the use of opioid medication,
feeding tubes, and potentially increase the risk of hospitalization (Murphy et al., 2009). Equally
important is that odynophagia may result in a noticeable decrease in QoL, health-related QoL,
and disease-free survival (McMenamin & Grant, 2015; Raber-Durlacher et al., 2011).
Odynophagia may cause the process of eating and drinking to become challenging or nearly
impossible (thus the necessity of a feeding tube). Additionally, eating and drinking may not be
pleasurable, and may take up a significant amount of time, impacting the patients’
desire/motivation to eat and drink (Raber-Durlacher et al., 2011). The potential for pain to
negatively impact oropharyngeal cancer patients is evident, and the fact that patients with
higher levels of pain tend to have feeding tubes inserted means their ability to take in the
required nutrition is compromised. Just like dysphagia, which may lead to a state of
compromised nutrition due to difficulty with swallowing, odynophagia makes getting adequate
levels of nutrition difficult simply because it hurts to do so. Enteral feeding can ensure
nutritional needs are met in both the case of painful swallowing resulting from toxicities (i.e.,
odynophagia), and also in the case of impaired swallowing function (i.e., dysphagia).
Mucosal damage. In addition to dysphagia, toxic chemotherapeutic agents and
radiation to the oral mucosa often damage the mucous membrane of the (aero)digestive tract,
leading to mucositis and more specifically, oral mucositis if the affected mucous lines the
oropharyngeal or oral region (Rastogi, Dwivedi, & Kazi, 2011). The subsequent inflammation of
the mucous membrane can lead to oral pain and discomfort, an increased predisposition to
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bacterial and fungal infections, and potentially severe ulcers that may last for five to seven
weeks post-treatment (Rodriguez-Caballero et all., 2012; Lockhart & Sonis, 1981; Stokman et
al., 2003). Pain associated with oral mucositis is exacerbated by movement of oral structures,
thus impacting one’s desire/ability to consume food orally. The risk for mucositis is increased by
the use of concurrent CRT (Rastogi et al., 2011).
Salivary glands. Another common side-effect affecting HNC patients is xerostomia - a
subjective complaint of dry mouth (Dirix, Nuyts, & Van den Bogaert, 2006). CRT is a common
cause of xerostomia (Pinna, Campus, Cumbo, Mura, & Milia, 2015), with damage to the salivary
glands resulting in reduced salivary output, and consequently leading to issues such as a sore
throat, oral discomfort/pain, dental decay, modified taste, and impaired ability to chew and
swallow (Pinna et al., 2015; de Graeff et al., 1999). Moreover, another complication of reduced
salivary output is compromised immunity, a consequence resulting from the role of saliva in
host defense of the oral cavity (Pinna et al., 2015).
More often than not, expressing the influence of subjective elements of health (e.g., the
subjective sensation of dry mouth) as measurable quantitative outcomes is challenging. For
xerostomia, however, this may not be the case. An investigation conducted by Kakoei et al.
(2012) found that instead of salivary flow being the main predictor of QoL (up to 6 months posttreatment), patients’ perception of xerostomia was more strongly correlated with changes in
QoL. QoL was noted to significantly worsen over time, while the severity of xerostomia
increased as well (Kakoei et al., 2012). The results indicate that a decrease in saliva and increase
in xerostomia resulting from therapy play an important role affecting QoL, seemingly making it
worse. In a recent study, Memtsa et al. (2017) corroborated the previous findings, in that the

20

subjective perception of xerostomia may strongly correlate with salivary flow, with QoL (as
measured by several functional scales) deteriorating at 6 months post-treatment as salivary
flow rate and xerostomia worsened as well (Memsta et al., 2017). Still, HNC patients may
expect some relief from xerostomia and its effect on QoL, since the findings from Memsta et al.
(2017) suggest a significant improvement in salivary flow in addition to the functional scales
used to represent QoL over time, approximating near-baseline levels by 12 months posttreatment.
With complications from CRT affecting the functioning of structures in the head and
neck, eating and drinking often become difficult and painful tasks (Guru et al., 2013).
Consequently, reductions in eating and drinking may lead to significant weight loss for patients
during treatment, and if the side effects experienced are severe enough, they may require
hospitalization (Piquet et al., 2002). In addition, weight loss percentage has also been shown to
be correlated with interruption of oncological treatment (Capuano et al., 2007). Interruptions
or delays in CRT treatment can be harmful or even fatal, potentially allowing for the
repopulation of cancer cells, negatively affecting the patient’s ability to effectively complete
treatment, in turn reducing the QoL and well-being of survivors (Guru et al., 2013; Shaw et al.,
2015).
Adequate Nutrition and Weight Management
Individuals being treated for HNC face many unique challenges, one of which is the
limited ability to ensure adequate nutritional intake before, during and after treatment.
Patients with advanced stage HNC are frequently affected by malnutrition, which is recognized
as a complication of HNC and its treatment (Bhayani et al., 2013). Weight loss can be a
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significant issue even prior to diagnosis, with the possibility of symptoms worsening as a result
of treatment and treatment-induced consequences. Evidence supports this claim, with research
showing that by the end of treatment, anywhere from 33-88% of HNC patients suffer from
malnutrition or weight loss (Languis et al., 2010). The maintenance of adequate nutrition
during treatment for HNC is crucial as it has the ability to improve bodily healing, reduce
treatment-related toxicity, morbidity, and mortality (Shaw et al., 2015). As a result of this
dynamic relationship, many radiation therapy centres have acknowledged importance of
preventing weight loss and have included nutritional support as an integral part of the
treatment they provide (Languis et al., 2010).
What separates HNC from other types of cancer is the critical location of the structural
and functional impairments that may emerge; namely, those related to eating, drinking,
swallowing, and voice and speech. As a consequence of having cancer in the upper
aerodigestive tract, the tongue, or floor of the mouth, patients will often experience difficulty
and pain while carrying out these complex, yet “taken-for-granted” everyday tasks (Gee, Kiraly,
McCarthy, & Martindale, 2012). Furthermore, these functional impairments are unique as they
present a challenge in terms of recovery. Maintaining adequate nutrition and preventing weight
loss are critical for improving prognosis as well as minimizing the suffering and damage caused
by the cancer and treatment. This maintenance is important as it can improve patients’ ability
to heal. Specifically with regard to HNC, the relationship between weight loss and survival has
been well documented and demonstrated in various studies (Languis et al., 2013; Shaw et al.,
2015).
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Consequently limiting their ability to recover effectively, weight loss has also been
associated with depression and depressive symptoms (Van Liew et al., 2016). Van Liew et al.
(2016) discovered that changes in depressive symptoms over time for HNC patients were
associated with same-month changes in weight loss. Not only is this an issue with regard to the
effect of depression on the mental health of HNC patients, but this evidence suggests that
depression is correlated with weight loss, directly and negatively the impacting treatment,
recovery and the quality of life of HNC patients (Van Liew et al., 2016).
The impact of poor nutrition and weight loss has also recently been shown to have a
significant prognostic effect on reducing survival outcomes for patients with HNC who are
receiving CRT (Languis et al., 2013). Poor nutrition and weight management is also an accepted
risk factor for intolerance of radiation therapy treatment (Gee et al., 2012). Furthermore, more
than a 10% reduction in weight from baseline, during or soon after treatment, has been
associated with a significant deterioration of factors such as social contact, social eating, and
QoL (Languis et al., 2013). Simply put, individuals undergoing CRT for HNC are at a greater risk
at baseline for malnutrition and dehydration. Not ensuring adequate nutrition and proper
weight management during treatment can exacerbate negative consequences, including a
reduction in muscle mass and functional capacity (Norman et al., 2005), increased risk of
cardiac arrest/failure, diminished quality of life (Shaw et al., 2015) and increased rates of
mortality (Correia, 2003). Accordingly, these changes may result in a cascade of negative
sequelae including interruptions in treatment, increased time of recovery, increases in
depressive symptoms, and even reduced survival (Gee et al., 2012; Shaw et al., 2015; Languis et
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al., 2013). As a result, the patients’ ability to follow through with CRT, receive effective
treatment, and live a pain-free, quality enriched life is drastically altered.
Enteral Feeding
Supporting HNC patients nutritionally is essential for managing symptoms of their
cancer as well as allowing for treatment to be administered without delays and/or
interruptions. This is often accomplished through the use of enteral feeding: the placement of
nutrients directly into the stomach or digestive system (DeLegge, 2007). In essence, the role of
enteral feeding is to supply individuals with their daily requirement of nutrients, including
macronutrients (proteins, carbohydrates and fats) in addition to vitamins and minerals. Because
the physical and functional issues associated with CRT mainly affect the head and neck area
causing difficulties with oral intake for oropharyngeal cancer patients, and because the stomach
and lower gastrointestinal tract are usually still intact and functional, providing feeding directly
into the stomach is considered effective and safe practice, and is thus commonly used during
treatment (Raykher et al., 2007).
Other than being utilized to maintain nutrition by avoiding oral intake (whether partially
or completely) due to insufficient swallowing capabilities or pain associated with swallowing,
enteral nutrition – when supplemented with different agents such as dietary fibre and arginine
– has demonstrated the ability to improve local wound complications and contribute to a
stronger immune system (de Luis, Aller, Izaola, Cuellar, & Terroba, 2002). Seeing as malnutrition
and immunosuppression are two characteristics associated with HNC patients (Riboli, Kaaks, &
Esteve, 1996), this may be considered a significant advantage of using enteral nutrition.
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Physicians confronted with this issue will commonly recommend a nasogastric (NG),
gastrostomy (G-tube) or a gastro-jejunostomy (G-J) feeding tube to assist with food intake
(Shaw et al., 2015). The latter two can be placed surgically or via a percutaneous approach.
Although they are similar in the role they play in providing nutritional support, these different
types of feeding tubes are not identical. NG feeding tubes offer more of a short-term solution,
when the impairments and issues with oral intake are not as severe (Nugent, Parker, &
McIntyre, 2010). Literature on this topic indicates that patients who are administered a NG
enteral feeding tube have a higher chance of having them removed earlier than patients who
are G-tube fed (Nugent et al., 2010). For more severe impairments, however, G-tubes tubes
provide a longer-term, and potentially more reliable and simple non-oral feeding solution.
Therefore, G-tube use is most often the choice when it comes to HNC patients receiving CRT
(Wermeker et al., 2012). Currently, a gastrostomy feeding tube may be preferred rather than a
NG tube for patients with radiation-induced oral and esophageal mucositis, offering several
advantages including enhanced mobility, a reduced length of hospital stay, and increased
patient satisfaction (Nugent et al., 2010). Developed by surgeons in the 1970’s, PEG is a
procedure commonly used to maintain the nutritional status of patients who are unable to
orally ingest food as a result of impaired swallowing or discomfort (Silander et al., 2012;
Bannister, 2016). The feeding tube, inserted through the wall of the abdomen and directly into
the stomach, allows patients who are unable to swallow to avoid regular feeding though the
upper aerodigestive tract while still acquiring adequate nutrition. Although initially developed
for children with chronic neurological disorders (Bannister, 2016), PEG feeding tubes are
commonly used as an adjunct to HNC treatment (Bossola, 2015). Since the obstructive tumour
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or treatment-related toxicities (e.g. mucositis and dysphagia) interfere with a patient’s ability to
swallow, tube feeding may be considered as a means of providing enteral nutrition to avoid
deterioration of their nutritional status and the associated risks.
In addition to nasogastric and G-tubes, HNC patients may be administered a G-J feeding
tube instead. G-J feeding tubes differ in that they include direct access not only to the stomach,
but the tube is placed further down into the jejunum - the middle section of the small intestine
- as well (Kwon et al., 2010). Just like with a G-tube, this method allows patients who are unable
to ingest a sufficient quantity of food to receive adequate nutrition while bypassing the regular
swallowing mechanism. Since this method involves the intake of nutrients directly into the
stomach/jejunum, it requires the stomach to function properly and the intestine to have
unimpaired absorptive capabilities (Blumenstein, Shastri, & Stein, 2014). Patients with issues
such as severe gastroesophageal reflux, gastric outlet obstruction, recurrent vomiting, and
feeding tube-related aspiration may be better off having a G-J tube to aid in nutrition and
weight management (Blumenstein et al., 2014). Although commonly used in some institutions,
literature relating to the use of G-J tubes in the HNC population is scarce, with the bulk of the
research almost exclusively tied to paediatric care. The various types of feeding tubes make the
decision of prescribing enteral feeding complicated and physicians must determine, based on
patient characteristics and treatment goals, which type is required for their patient. Further
complicating matters is the added factor of timing (i.e., should the tube be placed prior to
treatment, or during when issues present themselves), and what effect this has on treatment
and QoL.
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Prophylactic vs. reactive approach. Despite the well-documented advantages of
feeding tube placement in appropriately selected HNC patients, the timing of administration
continues to be a highly debated and controversial topic. Physicians and/or institutions (often a
program- or institution-level policy) will at times advocate for prophylactic insertion (i.e., prior
to the commencement of treatment) if the cancer is at an advanced stage or if patients are at a
high risk for malnutrition and other adverse events (e.g. dysphagia, oral mucositis, xerostomia).
Multiple studies show a significant benefit in weight management between a prophylactic
approach versus a reactive approach (i.e., insertion when physician deems it necessary based
on patient’s reaction to treatment), in favour of the prophylactic approach (Brown et al., 2016;
Wiggenraad et al., 2007; Lewis, Brody, Touger-Decker, & Epstein, 2014; Silander et al., 2012).
Furthermore, evidence also demonstrates a reduction in unplanned hospital admission for up
to one month post-treatment in patients who received prophylactic gastrostomy tubes versus
reactive tubes (Brown et al., 2016).
Using the prophylactic approach has been associated with fewer hospital admissions,
lower rates of dehydration, fewer treatment breaks due to radiation-related toxicities, and
lower medical costs (Shaw et al., 2015). In some instances, deciding to treat a patient in a
reactive/therapeutic manner when the patient can no longer sustain adequate oral nutrition
can also be associated with risk and uncertainty. The possibility of uncertainty is due to long
wait times for tube insertion, especially at facilities where resources are limited or there is a
high volume of patients (Shaw et al., 2015). As a consequence, these facilities may choose to
routinely place feeding tubes prophylactically for HNC patients undergoing CRT treatment
(Cady, 2007; Moor, Patterson, Kelly, & Paleri, 2010).
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Although the primary purpose of enteral feeding tube use is to improve nutrition and
weight management, the prophylactic approach may be doing patients a disservice in the long
run by altering their ability to regain independent eating. As previously mentioned, prophylactic
feeding tube placement has been shown to increase long-term dependence on enteral feeding,
negatively impacting long-term swallowing function (Langmore, Krisciunas, Miloro, Evans, &
Cheng, 2012), and further contributing to difficulty in weight management (Shaw et al., 2015).
Evidence also demonstrates that prophylactic feeding tube use may reduce a patient’s incentive
to continue oral intake, since they become dependent and overly comfortable with using the
feeding tube instead of orally ingesting their food (Shaw et al., 2015). Despite current research
claiming that prophylactic feeding tube placement is associated with an increased risk for
dysphagia (Chen et al., 2010), other studies have suggested that in fact, this relationship may
not exist (Silander, Jacobsson, Berteus-Forslund, & Hamerlid, 2013; Silander et al., 2012).
As a result of many contradictory studies on the advantages and disadvantages of each
approach, it remains undecided whether or not prophylactic feeding tube placement provides
an advantage to patients with regard to survival and health-related outcomes compared to the
reactive approach (when patients are supported with an enteral feeding tube once it becomes
difficult to maintain their nutritional status and weight). It may be concluded that neither
approach can be generalized as being ideal for every patient. Instead, a more tailored and
specific approach may be necessary to determine optimal timing of insertion, as well as
whether or not enteral feeding is necessary at all. Despite the lack of consensus and ongoing
debate, it is agreed upon that many HNC patients will require a feeding tube for nutritional
support (Bhayani et al., 2013). Therefore it is extremely important to understand the short and
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long-term impact of feeding tube status on health, swallowing-related outcomes and overall
QoL. Specific inquiry into outcome variables related to health, swallowing and QoL may be the
most effective way to determine the impact of feeding tube use on health and swallowingrelated outcomes, rather than simply addressing prophylactic versus reactive methods.
Feeding tube status. Much of the available literature investigating differences between
enteral methods of feeding compare prophylactic PEG tubes, reactive PEG tubes and
nasogastric feeding tubes to one another. Very few studies directly compare a group of patients
with a feeding tube to those without. For example, a meta-analysis performed by Zhang, Zhu,
Zhang, & Wan (2015) comparing the effects of various methods of enteral feeding did not
include a ‘no feeding tube’ group in their final write up of results, despite finding some studies
using this group in their search. There was an emphasis on comparing prophylactic and reactive
methods with nasogastric feeding tubes, with the conclusion that prophylactically placed PEG
tubes may be a superior choice in the management of malnutrition (Zhang et al., 2015). Other
studies do in fact include a control group consisting of patients who have not been
administered a feeding tube. However, these investigations often compare a prophylactic
approach to a heterogeneous control group. In other words, the control group consists of
patients who have not received a feeding tube prophylactically, but also includes patients
administered a tube under the reactive approach if required during treatment.
A retrospective review by Chang et al. (2009) included a control group of patients who
did not receive a prophylactic feeding tube, however within the control group, nasogastric
feeding tubes were used when the physician decided the patient was unable to maintain
enough nutrition orally or had lost too much weight (usually around 5% or more of their
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baseline weight). This type of grouping consequently lead to a control group with a mix of
patients: those who did not receive a feeding tube, in addition to patients who received
reactive nasogastric feeding tubes (Chang et al., 2009). Despite the apparent issues, many other
studies share this type of methodology (Brown et al., 2018; Silander et al., 2011; Langmore et
al., 2012; Lee et al., 1998). Due to the mixing of patients in control groups for the studies cited
above, the results are not applicable in the context of this investigation, and may be difficult to
extend to real-world settings. A clear need for direct comparison between patients based on
their absolute feeding tube status is evident.
Rather than include patients prescribed the reactive method and no feeding tube at all
in the same group, Quon et al. (2015) included three groups when comparing patient pretreatment characteristics and functional outcomes of HNC patients: a reactive group, a
prophylactic group, and a group of patients who did not receive any feeding tube during
treatment. This type of grouping allows for more accurate and externally valid comparisons
between very specific groups of patients. A significant finding in this study was that when
comparing all three groups, patients who did not require a feeding tube had a lower tumour
and overall stage, fewer sessions of concurrent chemotherapy treatment, as well as less pretreatment dysphagia and weight loss. In addition, significant baseline differences were found
between the reactive and no feeding tube groups, as well as between the prophylactic and no
feeding tube groups (Quon et al., 2015). These findings suggest that all three of these groups
were inherently different, and that they cannot be grouped into the same category if
meaningful results are to be obtained. Although this investigation seems to effectively group
participants based on feeding tube status, many received RT in 2004-2007, meaning that 3D-
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conformal radiation therapy was the primary treatment modality. The remainder (from years
2008 and 2009) were treated with IMRT (Quon et al., 2015), again contributing to a lack of
homogeneity within the groups.
While the majority of studies have assessed individuals who did not use a feeding tube
as a control group to test for differences, Lewis et al. (2014) used a ‘no feeding tube’ group as a
primary group for comparison. Results indicate that patients without a feeding tube had a
significantly higher body mass index (BMI) and significantly less chemotherapy cycles when
compared to patients with prophylactic feeding tube insertion. In contrast, patients without a
feeding tube also lost significantly more weight than those in both other groups (Lewis et al.,
2014). While this study does separate the reactive and no feeding tube groups, the use of many
different types of HNC (oropharyngeal, laryngeal, etc.) takes away from producing results that
can be applied to a specific population outside the context of the investigation (Lewis et al.,
2014). To gain a better understanding of the role that feeding tube status plays in short- and
long-term treatment outcomes, inquiry should be done examining a specific, homogeneous
group of patients.
Transition to Oral Feeding
An important factor to consider when deciding to administer a feeding tube is the
possibility of dependence on enteral feeding. Ideally, feeding tubes are administered to
patients when they need them, and removed once the patient is able to consume food orally
without pain or issues. As previously described, multiple studies support the prophylactic
placement of PEG feeding tubes to prevent outcomes such as weight loss and dehydration,
which in turn help the patient complete treatment without interruption. However, there is
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evidence to support the claim that this approach may lead to long-term dependence on enteral
feeding, in turn contributing to the development of esophageal toxicity and dysphagia (Bhayani
et al., 2013). Many patients who have feeding tubes go through lengthy periods without oral
intake, which has also been demonstrated to be predictive of long-term dependence (Bhayani
et al., 2013).
Prophylactically-placed feeding tubes also have a higher rate of unnecessary placement
(almost 50% as per the definitions provided by Madhoun et al.), with one study finding an
increased likelihood of prolonged dependence, especially with advanced T-stage and preexisting dysphagia (Verma et al., 2015). For these reasons, the evident risks to functional
outcomes associated with prophylactic PEG tube insertion cannot be ignored; consequently
emphasis should be placed on customization of treatment plans according to patients and their
feeding tube use in order to ensure the potential benefits outweigh these risks. Identifying the
effect that maintained oral intake has on PEG dependence is especially important for limiting
these damaging consequences.
With growing evidence supporting the idea that the prophylactic approach may indeed
place HNC patients at an increased risk for dependence and dependence-related outcomes,
priority should be placed on maximizing the amount of oral intake during treatment, even if the
patient has a feeding tube. In order to so, the ideal amount of oral intake during treatment
should be decided and treatment goals planned accordingly. While many studies do assess the
impact on health outcomes in order to determine whether or not a method of enteral feeding
is effective, examining the effect of tube status on oral intake and on swallowing outcomes
during treatment can offer more information on how dependence affects the patient. Further
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investigating how oral intake and dependence may change over time, depending on whether or
not a patient has a feeding tube inserted, will supplement this understanding of dependence
and the ways in which it can be avoided.
Maintained Oral Intake
Patients who report adherence to swallowing exercises are significantly less likely to
have any form of feeding tube administered to them compared to those who do not report
adherence (Bhayani et al., 2013; Hutcheson et al., 2013). Research has also shown that patients
actively exercising the swallowing muscles during treatment are better able to maintain
swallowing function (Carnaby-Mann, Crary, Schmalfuss, & Amdur, 2012). One form of exercise
is continued oral intake during treatment, which may be influenced by the use of and
dependence on feeding tubes. Continued oral intake may not be restricted when a feeding tube
is inserted, however, patients may feel satiated by the tube alone. Also, with significant pain in
the upper aerodigestive tract, patients may no longer wish to eat by mouth (Starmer et al.,
2015).
Pain caused by acute toxicities such as mucositis and the associated dependence on
tube feeding in turn decrease the regular resistive load placed on the swallowing mechanism,
leading to disuse atrophy, or a decrease in the size of the muscle (e.g. pharyngeal constrictor
muscle atrophy; Kasper, Talbot, & Gaines, 2002; Clark, 2009) . In addition, negative swallowing
outcomes resulting from a reduction in swallowing activity during feeding tube use can be
attributed to the effects of pharyngeal fibrosis of tissues (Corry et al., 2008; Gillespie et al.,
2006; Crombie et al., 2013). In this case, neglecting to use the muscles necessary for the
swallowing mechanism by reducing oral intake encourages adverse remodelling of these
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muscles, or atrophy, leading to a worsening of symptoms (Kasper et al., 2002; Clark, 2009).
Over time, atrophy resulting from disuse of muscles necessary for the swallowing mechanism
leads to a reduction in muscle strength, irregular motor control, and increased muscle fatigue
(Hutcheson et al., 2013). Therefore, the effect of muscle wasting and the remodelling of
musculature has led to the adoption of a “use it or lose it” approach to treatment, emphasizing
the importance of continuing oral intake even when a feeding tube has been inserted
(Hutcheson et al., 2013).
Research has found proactive swallowing exercises to lead to better swallowing-related
QoL (Kulbersh et al., 2006; Shinn et al., 2013), lower rates of feeding tube placement (Bhayani
et al., 2013), superior tongue and base and epiglotic movement (Caroll et al., 2008), and shorter
duration of PEG dependence (Bhayani et al., 2013). Randomized controlled trials by CarnabyMann et al. (2012) and Kotz et al. (2012) investigated the use of swallowing
exercises/interventions on swallowing-related outcomes, both reaching a similar conclusion:
patients who performed swallowing exercises had better swallowing-related health outcomes
than those who did not. While there was no inquiry into how maintaining oral intake would
affect swallowing-related outcomes, the conclusion that using musculature responsible for the
swallowing mechanism during CRT treatment through the implementation of swallowing
exercises (e.g. tongue press, hard swallow, Therabite, Effortful Swallow, and tongue base
retraction) aids in the improvement of swallowing functionality is extremely valuable.
Maintaining oral intake during treatment would serve a similar purpose. That is,
exercising the muscles by putting them through the regular swallowing mechanism would in
turn reduce muscle atrophy and adverse remodelling, leading to improved swallowing for
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patients despite the administration of a feeding tube. Supporting this claim is an investigation
conducted by Ames et al. (2011), which compared the effects of continued oral intake during
tube placement on nutritional outcomes in HNC patients. The results were somewhat
predictable, finding that patients with absolutely no oral intake (39% of 91) were more likely to
have advanced disease as well as significantly worse observed survival (Ames et al., 2011).
Patients who maintained oral intake while having a feeding tube in place, then subsequently
had their tube removed had a higher likelihood of maintaining their weight and were more
likely to report eating scores in a high-functioning category (Ames et al., 2011). Thus, by
encouraging maintained oral intake, the same benefits could potentially be had, without the
need to implement additional exercises or therapy for patients.
Statement of Problem
While research has demonstrated that feeding tubes can be beneficial to patients
undergoing CRT for HNC, there is a lack of consensus on ideal timing of insertion based on
patient characteristics. Both prophylactically (i.e., before treatment) or reactively (i.e., during
or following treatment when oral intake is insufficient) inserted feeding tubes have proven to
be useful in minimizing the risks associated with treatment side-effects (Wiggenraad et al.,
2007; Lewis et al., 2014; Silander et al., 2012; Shaw et al., 2015). Nonetheless, a superior
method has yet to be identified. A systematic review by Shaw et al. (2015) examined which
approach was superior in limiting weight loss during treatment, only to identify that out of 15
studies, only 6 found statistically significant differences between the two methods of
administration. The remainder of studies concluded that differences were non-significant, with
two of the studies reporting no significant differences between these two approaches (Shaw et
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al., 2015). Determining whether patients are at risk for adverse events related to malnutrition
and weight loss is critical in deciding whether or not a feeding tube will be a necessary part of
patient care. Having the ability to predict the impact of enteral feeding on health outcomes
based on feeding tube status has the potential to address risk factors associated with both the
prophylactic and reactive approach, with the added benefit of figuring out how patients with
feeding tubes compare to those without.
While attempts have been made to develop a standardized protocol to guide the
decision making process, there is currently no consensus on the optimal timing of feeding tube
insertion for HNC patients undergoing CRT treatment (Kramer, Newcomb, Hessler, & Siddiqui,
2014). The development and validation of guidelines for feeding tube administration for highrisk HNC patients by Brown et al. (2013) has proven to be useful in decreasing the amount of
unplanned hospital admissions, reducing interruptions in treatment (Hughes et al., 2013) and
contributing to improved nutritional outcomes (Brown et al., 2013). However, this approach is
dependent on the assumption that patients will be treated with a proactive approach, hence
limiting its ability to contribute to decisions regarding timing of insertion for the general HNC
population. Still, further research is necessary in order to decide on a standardized protocol,
“with consideration of patients’ disease characteristics and baseline feeding capacity” (Kramer
et al., 2014).
All currently available evidence suggests that a standardized protocol specific to the
timing of tube insertion in HNC patients is unavailable. However, if evidence can be generated
to guide standardization, the ability to maximize positive health outcomes after insertion may
be possible. To address this shortcoming in the field of enteral nutrition, attention should also
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be placed on improving the physician’s ability to communicate and set goals for patients based
on their feeding tube status and their ability to maintain oral intake, regardless of the timing of
insertion. Because no standardized protocol exists to aid physicians in the decision making
process for when, or even if to administer a feeding tube (Kramer et al., 2014), this raises
considerable clinical concerns. Given the discrepancy in findings comparing prophylactic and
reactive tube feeding, questions regarding which type of approach is ideal remain unanswered,
and there remains “a critical void in the current literature” (Shaw et al., 2015).
One particular factor that may contribute to the varied results across studies is the
general lack of attention that is given to the actual use of the feeding tubes. Administration of a
feeding tube does not ensure consistent usage between patients, since how much it is actually
used may vary widely depending on the patients’ needs. If two patients have been
administered a feeding tube prophylactically, existing studies have grouped these two patient
cohorts together. Although some patients may share the same method of administration, how
much they rely on enteral feeding will most likely vary, as some are able to eat a higher
percentage of their diet orally compared to others. Moreover, this commonly used
methodology fails to take into account patients without a feeding tube, thus ignoring a large
portion of HNC patients and their needs/treatment outcomes. Examining the amount of
maintained oral intake with whichever approach is used (prophylactic vs. reactive) may provide
information of greater value. In turn, this may allow researchers to group the patients into
more homogeneous groups based on how much they use the tube, regardless of which method
was prescribed. By comparing outcomes such as oral intake and swallowing function based on
feeding tube status, then further investigating how these outcomes change for each group over
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time, this study will attempt to limit the shortcomings of previous research investigations listed
above.
Information comparing differences based on a more objective measure of oral intake
has the potential to greatly improve communication between physician and patient. The ability
to disclose long-term expectations on swallowing-related outcomes based on feeding tube
status could greatly enhance the clarity of the situation in terms of prognosis and recovery,
ultimately allowing for timely and precise patient education, and improved communication in a
clinical setting. This would offer more comfort to patients, who are experiencing ongoing
psychological and emotional challenges in addition to the physical pain of having the cancer
and receiving treatment. It has been reported that patients desire as much detailed information
as possible regarding their prognosis, even if the news is negative (Fujimori & Uchitomi, 2009).
Therefore, by identifying the impact of feeding tube status on oral intake, swallowing-related
QoL, weight, and feeding tube dependence, and further investigating how these variables
change over time, side-effects secondary to radiation treatment and weight management can
be better managed and improved.
Objectives
Based on collective information provided in the preceding review and the fact that little
is known about feeding tube status on individual health, swallowing and QoL in a reactive
model, many questions emerge. Consequently, the prior review provides information that
warrants investigation into differences between patients with a reactively placed feeding tube,
and a control group (patients without a feeding tube). Therefore, the purpose of the proposed
research investigation seeks to address the impact of feeding tube status on health outcomes
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of patients undergoing chemoradiation therapy treatment for HNC. More specifically, this
investigation seeks to:
1) Determine if baseline characteristics predict feeding tube use and dependence for
individuals diagnosed with oropharyngeal cancer which was treated with IMRT.
2) Investigate the impact of feeding tube status on long-term swallowing-related
outcomes, weight loss and QoL.
3) Describe differences in the trajectory of recovery for outcome measures based on
feeding tube use.
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Chapter 2: Method
Participants
A retrospective chart review was conducted for patients with oropharyngeal squamous
cell carcinoma that was treated with definitive RT or CRT London Health Sciences Centre –
Victoria Hospital between January 2013 and December 2015. After preliminary review of the
medical records of 1197 consecutive patients, 126 eligible patients were selected based on the
criteria above. Patients were excluded from the study based on the following criteria: (1)
primary surgical treatment or surgery within 12 months post-radiation therapy, (2) patient’s
decline of curative treatment (i.e., pursued palliative means of care), and/or (3) distant tumour
metastasis leading to a change in treatment strategy (e.g., more centred on palliative care,
with less involvement of allied health professionals).
Additionally, retrospective data was collected on demographic and treatment
characteristics from electronic medical records. This included information on age, sex, tumour
staging (T and N classification), type of treatment (RT or CRT), p16 status (as a surrogate marker
of HPV status), radiation dose, the type of drugs used for chemotherapy and comorbidities.
Data was also collected on variables to be used as primary outcome measures, including the
FOIS, MDADI, PSS-HN, and weight. Outcome variable data was collected at baseline
(immediately prior to treatment), and at 3, 6, and 12 months post-treatment.
For patients who received a feeding tube at some point during RT/CRT treatment,
information was collected about the type of tube, timing of placement, and duration of
placement (calculated based on date of insertion and data of removal). The first patient group
consisted of oropharyngeal cancer patients who have had a feeding tube inserted during their
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RT/CRT treatment (FT group). The second group used in this investigation consisted of
oropharyngeal cancer patients who had not had a FT inserted over the course of their RT/CRT
treatment (NFT group). The exclusion criteria for the second patient group were identical to the
first (FT) patient group.
Baseline Patient and Treatment Characteristics
One hundred twenty-six patients with oropharyngeal cancer who met the inclusion
criteria were included in this investigation. In this sample, 40 patients (32%) were administered
a FT, whereas 86 patients (68%) completed treatment without requiring enteral nutrition. The
median age of all included patients was 60.5 years (range, 31-89). For the FT group, the median
age was 63 years (range, 44-77), and for the NFT group it was 60 years (range, 31-89). Overall,
107 (85%) of patients were male, with 32 (80%) males in the FT group and 75 (86%) males in
the NFT group.
For the 40 patients who were administered a FT, 38 (95%) received a G-J tube, while
only 2 (5%) received a G- tube. The most common tumour staging for both groups combined
was T2 (51 patients; 41%) and T3 (28 patients; 22%), followed by T1 (25 patients; 20%) and T4
(21 patients; 17%). Within the FT group, the most common tumour staging was T2 (13 patients;
33%), followed by T4 (11 patients; 28%) and T3 (9 patients; 23%). As for the NFT experimental
group, T2 tumour staging was most prevalent (38 patients; 44%), followed by T1 and T3, which
were both identical (19 patients; 22.1%). Based on eligibility criteria, only patients undergoing
primary CRT or RT treatment were included in the study.
Overall, the majority of patients received CRT (114 patients; 91%), with the remainder
receiving RT alone (12 patients; 10%). When divided into groups based on FT placement, those

41

with a FT largely received CRT (38 patients; 95%). Patients without a feeding tube also mainly
received CRT (76 patients; 88%). All patients received IMRT as the type of RT. Bivariate
associations (with respect to FT status) using chi-square tests yielded no significant results for
sex, tumour and lymph node staging, and treatment type at baseline. Additional information on
patient-related characteristics is summarized below in Table 1.
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Table 1
Demographics for Oropharyngeal Cancer Patients from 2013 to 2015
Characteristics
Overall
FT
NFT
Number of participants 126
40
86
Age in years at
enrollment
Mean, median (range) 60.14, 60.5 (31-89) 61.75, 63 (44-77) 59.40, 60 (31-89)
Sex: male, N(%)
107(84.9%)
32(80.0%)
75(87.2%)
Tumour staging, N(%)
X
1(0.8%)
1(2.5%)
0(0.0%)
0
0(0.0%)
0(0.0%)
0(0.0%)
1
25(19.8%)
6(15.0%)
19(22.1%)
2
51(40.5%)
13(32.5%)
38(44.2%)
3
28(22.2%)
9(22.5%)
19(22.1%)
4
21(16.7%)
11(27.5%)
10(11.6%)
Nodes, N(%)
N0
14(11.1%)
3(7.5%)
11(12.8%)
N1
10(7.9%)
3(7.5%)
7(8.1%)
N2a, N2b, N2c
94(74.6%)
29(72.5%)
65(75.6%)
N3, N3b
8(6.3%)
5(12.5%)
3(3.5%)
Treatment Regimen
N(%)
Radiotherapy alone
12(9.5%)
2(5.0%)
10(11.6%)
Radiotherapy plus
chemotherapy
114(90.5%)
38(95.0%)
76(88.4%)
Alpha = 0.05 (2-tailed)
* denotes significant p value
p values were obtained using the Chi-Square test for categorical variables

p value

0.292
0.096

0.238

0.238
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Outcome Measures
Functional Oral Intake Scale (FOIS). The Functional Oral Intake Scale (FOIS), which is a
tool created to document the functional level of oral intake of food/liquids for patients
experiencing dysphagia (Crary, Carnaby Mann, & Groher, 2005), was recorded for each patient
and was used as a surrogate marker for maintained oral intake during treatment. This validated,
seven-point ordinal scale reflects changes in oral intake of food/liquids over time, and is a
suitable tool for the clinical documentation of change in functional oral intake and oral dietary
tolerance (Crary et al., 2005). The scale was chosen to give insight into how much of the
patient’s diet is consumed orally in relation to enteral intake, ranging from complete
dependence on tube feeding (1 point) to tolerance of an oral diet with no restrictions (7 points;
Crary et al., 2005; Kotz et al., 2012). Since this investigation placed emphasis on investigating
the effects of maintained oral intake over the course of treatment on swallowing-related
outcomes, the FOIS was used as a marker of maintained oral intake.
Performance Status Scale (PSS-HN). The PSS-HN offers a quantifiable rating of various
eating habits based on reports from patients and has been validated as a speech and
swallowing outcome measure (List, Ritter-Sterr, & Lansky, 1990). Consisting of three differing
subscales, Normalcy of Diet, Understandability of Speech, and Eating in Public, patients report
on each subscale with a score ranging from zero to 100, with a higher score being indicative of
better functioning (List et al., 1990). The Normalcy of Diet subscale was thought to be most
relevant to this investigation, as it is used to assess the degree to which a patient is able to
tolerate a normal diet (List et al., 1990). Foods easier to eat (e.g., pureed foods) are situated at
the low end of the scale, generating a lower score, while foods that are more difficult to eat
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(e.g., peanuts) occur at the high end of the scale, and will generate a higher score (List et al.,
1990). By using the PSS-HN (Normalcy of Diet) variable in addition to the FOIS, this research
study sought to provide a comprehensive description of how maintained oral intake affects the
QoL of patients inside and outside of clinical settings.
M.D. Anderson Dysphagia Inventory. The M. D. Anderson Dysphagia Inventory
(MDADI) is a validated dysphagia-specific QoL questionnaire (Chen et al., 2001) which allowed
for specific inquiry into the impact of treatment on this study’s population. The patientreported questionnaire includes 20 items, with each item being rated on a 5-pont scale. The
overall score is summarized, ranging from 20 (e.g., 1 point for every item) to 100 (e.g., 5 points
for every item). A superior outcome is represented by higher score on the MDADI, and a
fluctuation of 10 points or more indicates a clinically significant difference (Goff et al., 2017).
After its introduction into medical literature in 2001, the MDADI has become a widely-used and
popular patient-reported outcome (PRO) measure of swallowing-related QoL.
A review of the literature indicated that MDADI measures are reported in greater than
40 research publications, with validation of the PRO measure being presented in five different
languages (Schindler et al., 2008; Speyer et al., 2011; Carlsson et al., 2012; Guedes, Angelis,
Chen, Kowalski, & Vartanian, 2013; Kwon, Kim, Park, Byung-Mo, & Han, 2013). Given the
extensive adoption of the MDADI in medical literature and its use world-wide, the MDADI is
arguably the main PRO measure of dysphagia in HNC research. In addition to being the most
commonly used patient-reported outcome metric (Geopfert et al., 2016), the MDADI has a
multi-factorial approach to evaluating swallowing based on questions related to the functional,
physical and emotional impact of their perceived function (Chen et al., 2001; Gillespie, Brodsky,
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Day, Lee, & Martin-Harris, 2004; Yang et al., 2015; Geopfert et al., 2016). By doing so, the
MDADI allows researchers/physicians to determine how patients view their swallowing
capability during and after treatment, and how this in turn affects their QoL and overall health
(Chen et al., 2001).
Therefore, by evaluating the effect of dysphagia on the QoL of patients using the
MDADI, a connection can be established between how maintained oral intake (measured using
the FOIS) influences swallowing-related outcomes and whether this relationship changes over
the course of treatment. The functional subscale was utilized to assess the impact of dysphagia
on patients’ daily activities in an attempt to understand how treatment- and/or cancer-related
difficulties impact QoL (Chen et al., 2001). Additionally, the composite MDADI score, which
provides a summary of the MDADI as a weighted average of three other subscales (functional,
emotional and physical), was also used as a primary outcome measure. The decision to use the
composite scale was primarily based on the fact that it summarizes overall performance on 19items present in the MDADI. Furthermore, the composite score has been demonstrated to be
less variable (low standard deviation) and have high consistency when compared to clinical
anchors of swallowing function. In addition, the composite score of the MDADI has been shown
to have real-world carry over, with a change of 10 points being associated with clinically
meaningful differences in swallowing function (Hutcheson et al., 2016).
Data Analysis
Following data collection, descriptive statistics were used to obtain measures of central
tendency for all outcome variables. Bivariate associations for categorical outcomes (FT status)
were analyzed using the chi-square test (Daniel & Cross, 2013). For continuous outcome
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variables such as the duration of G-tube tube placement, between-group differences (FT vs.
NFT) were examined using Student’s t-test (Daniel & Cross, 2013). Statistical analyses to test for
within-group differences for normally distributed variables (using Linear Mixed Effects analysis)
and the non-normally distributed FOIS variable (using the Skilling’s Mack test) were performed
using R statistical software (R Core Team, 2018). The following statistical packages were
utilized: lme4 (Bates, Maechler, Bolker, & Walker, 2015), lmerTest (Kuznetsova, Brockhoff, &
Christensen, 2017), lsmeans (Lenth, 2016), and Skillings.Mack (Srisuradetchai, 2015). All other
analyses were completed using SPSS (version 25.0) statistical software. The alpha value for
between and within group comparisons was set at 0.05, and at 0.0083 for post-hoc pairwise
comparisons. The decision to utilize 0.0083 as the alpha value was based on the need to adjust
for multiple comparisons across 6 post-hoc tests (Bonferroni correction). The primary focus of
this investigation was direct comparisons between the two treatment groups. The variables
collected (FOIS, MDADI, PSS-HN, weight, FT duration) were used as the primary outcome
measures when comparing the two groups, with the intention of exploring the potential
differences between the two in terms of their diet, health, swallowing, and overall QoL.
Feeding tube dependency. To determine if variables (or groups of variables) are able to
predict dependence on tube feeding, a multiple linear regression analysis was performed. This
was done with the intention of estimating and fitting a structural model to explain variation in
the values of the dependent variable (duration of FT use) in relation to the independent
variable(s) of interest. As a result, the variables (or combinations of variables) significantly
affecting duration of FT use and estimates of the magnitude of their contribution were
determined and expressed as a coefficient of multiple determination (or R2 value; Evans, 2014).
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Between-group comparison. All outcome variables were analyzed to determine
normality of distribution and to guide the selection of appropriate statistical tests. While most
of the variables were normally distributed (weight, MDADI subscales, PSS-HN subscales, and
duration of use), data from the FOIS presented a unique challenge. Initial inquiry showed a
frequency histogram skewed to the left, which indicated that the spread of this variable was
non-normal (also confirmed with Levene’s test for normality). As a result, standard parametric
tests like the independent sample t-test, paired t-test, and ANOVA were not used for statistical
analysis (Evans, 2014). In order to test between group differences for the FOIS, the
nonparametric Mann-Whitney U/ Wilcoxon Rank Sum test was used in place of the
independent samples t-test (Evans, 2014; Daniel & Cross, 2013). Frequency histograms and
Levene’s test for normality indicated that the other outcome measures (MDADI, PSS-HN,
weight, FT duration) were normally distributed, thus independent samples t-tests were used for
between group comparisons (Evans, 2014). An alpha value of 0.05 was applied to all statistical
tests mentioned above.
Within-group comparison. Within group analyses was also performed in order to
determine how each group changed over time, specifically at baseline, 3, 6, and 12 months.
Typically, to investigate differences within groups, a one-way repeated measures ANOVA would
be the statistical test of choice (Daniel & Cross, 2013). However, as a result of the non-normal
distribution of the FOIS, and the presence of missing-at-random values, the Skillings-Mack test
test was selected as the nonparametric alternative to be used (Evans, 2014). Important to note
is the requirement of this statistical test to remove any block/participant with only one
observation (Chatfield & Mander, 2009). Despite the removal of participants with only one

48

measurement, the sample sizes used were still sufficient enough to produce meaningful and
statistically sound results.
If statistical significance was observed for either group with respect to the FOIS (p <
0.05), post-hoc analysis was conducted to determine where that difference is. The nonparametric Wilcoxon Signed-Rank Test (alternative to dependent samples t-test) was used for
post-hoc analysis since the main purpose of this test is to investigate differences for the same
individual between two points in time (Daniel & Cross, 2013; Evans, 2014). Additionally, since
the sample sizes are reasonably large (≥20 participants), the sampling distribution approached
normality, thus allowing for the z-statistic to be used for significance testing (Daniel & Cross,
2013). Resulting from the use of four time points (baseline, 3 months, 6 months, and 12
months), there was a total of six post-hoc tests performed, thus lowering the alpha value of
each post-hoc analysis to 0.0083 (0.05 / 6). By using this approach, known as the Bonferroni
correction, the chance of obtaining a false-positive result/type 1 error was reduced (Daniel &
Cross, 2013).
The variability in sample size within each group was cause for adjustment even for the
normally distributed variables, such as the MDADI, PSS-HN, weight, and FT duration. Rather
than using the parametric repeated measures ANOVA for these variables, a Linear Mixed
Effects (LME) analysis was used to test if there is a difference across time for each group (Bates,
Machler, Bolker, & Walker, 2014). By using LME, participants with data missing at random can
still be included in the analysis, despite the resulting variations in sample size (Bates, Machler,
Bolker, & Walker, 2014). However, as with the Skillings-Mack test, participants with only one
measurement were excluded from analysis. Data from participants with no baseline
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measurement were excluded as well. Dependent samples t-tests were utilized in post-hoc
analysis to compare all time points to one another (Evans, 2014), with the alpha value once
again set at 0.0083 based on the Bonferroni correction. As a result of the different sample
variances and varying sample sizes at each point in time, the Satterthwaite approximation was
used to calculate the degrees of freedom for each t-test (DiSantostefano & Muller, 1995).
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Chapter 3: Results
Baseline Characteristics
Analyses were performed at baseline to determine which factors distinguish those who
received a FT from those who did not. For the FOIS, no significant difference was observed at
baseline (p = .096). Between group comparisons for differences in weight revealed baseline
weight to be significantly lower for the FT group compared to the NFT group (p = .003). The
MDADI subscales used in this investigation (functional and composite) were found not to be
significantly different at baseline when comparing the two patient groups. Similarly, baseline
PSS-HN (Normalcy of Diet) scores were not significantly different between the FT and NFT
groups.
Feeding Tube Dependency
A multiple linear regression analysis was performed to explain the relationship between
duration of FT use and the various outcome variables of interest (e.g., FOIS, PSS-HN, MDADI,
and weight) at baseline and 3 months post-treatment. The findings suggest that these variables
are far more effective at predicting duration of FT use when data were used from the 3 month
time point (Table 3), compared to using baseline data (Table 2).
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Table 2
Multiple Linear Regression on FT Duration at Baseline
Independent Variable(s)

Sample Size (n)

R2 Value

Weight

29

0.133

FOIS + PSS(Diet) + MDADI(C) + MDADI(F) + Weight

23

0.050

FOIS + PSS(Diet)

33

0.026

PSS (Diet)

33

0.035

FOIS + MDADI(C) + MDADI(F)

30

0.033

PSS(Diet) + MDADI(C) + MDADI(F)

30

0.031

MDADI(C) + MDADI(F)

30

0.031

FOIS

33

0.029

MDADI (C)

30

0.023

PSS(Diet) + MDADI(F)

30

0.015

MDADI (F)

30

0.012
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Table 3
Multiple Linear Regression on FT Duration at 3 Months Post-Treatment
Independent Variable(s)

Sample Size

R2 Value

(n)
FOIS + PSS(Diet) + MDADI(C) + MDADI(F) + Weight

9

0.740

FOIS + PSS (Diet) + MDADI(C) + MDADI(F)

19

0.463

FOIS + MDADI (C) + MDADI (F)

19

0.452

PSS (Diet) + MDADI (C) + MDADI (F)

19

0.374

MDADI (C) + MDADI (F)

19

0.363

PSS (Diet) + MDADI (F)

20

0.288

MDADI (F)

20

0.286

FOIS + PSS (Diet)

31

0.237

FOIS

31

0.236

PSS (Diet)

31

0.162

MDADI(C)

19

0.156

Weight Loss

19

0.021
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Feeding Tube Status
Maintained oral intake. The FOIS variable was used as a marker of maintained oral
intake, and was collected at baseline, as well as 3, 6, and 12 months post-treatment. When
comparing the two experimental groups on this metric, a significant difference was observed
only at 3 months (p = .003) and at 6 months (p = .005), indicating that FOIS scores at both points
in time were significantly lower for the FT group (Figure 1). No significant difference was
observed at 12 months post-treatment (p = .965). Analyses performed to test within group
differences over time found a significant relationship between FT status and FOIS score from
baseline to 12 months post-treatment for each group. For the FT group, post-hoc analysis
revealed baseline FOIS scores to be significantly higher than FOIS scores at 3 months (p = <.001)
as well as 6 months (p = .007). As for the NFT group, post-hoc analysis showed a significant
difference between baseline and 3 months (p = <.001), baseline and 6 months (p = .007), and
baseline and 1 year (p = .001), indicating that baseline scores were significantly higher for this
group at these specific points in time post-treatment.

Figure 1. Distribution of FOIS Scores According to Feeding Tube Status.
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Normalcy of diet. Between group comparisons using the PSS-HN (Normalcy of Diet)
scale yielded no significant differences. Repeated measures analyses performed on both
patient groups also revealed no significant differences over time.
Dysphagia and QoL. Two MDADI subscales were used in order to compare the two
patient groups. For the functional MDADI subscale, there were no significant differences found
between the two groups when comparing their scores at the four time points. Similar results
were obtained for the composite subscale, except that at 3 months post-treatment, patients in
the FT group had a significantly lower mean MDADI-composite score (p = .046).
Repeated measures analysis using linear mixed effects found a significant change in
MDADI-functional scores over time for patients in the NFT group (p = .020). Post-hoc analysis
using the independent samples t-test (with the Satterthwaite method for calculating degrees of
freedom) found mean baseline MDADI-functional scores to be significantly higher when
compared to 3 months (p < .001) and 6 months as well (p = <.001). Similarly, MDADI-composite
scores were found to be significantly different over time (Figure 2) in the NFT group (p < .001).
Further analysis revealed baseline MDADI-composite scores to be significantly higher than
scores at 3 months (p < .001) and at 6 months (p < .001). There was no significant change over
time in MDADI-functional (p = .548) and MDADI-composite scores for p = .179) the FT group.
Clinically significant changes in the MDADI-composite subscale were investigated as well
(Figures 3 and 4). For this subscale, a change in either direction of 10 points or more is
considered to be significant in a real-world, clinical setting (Hutcheson et al., 2015).
Investigating these changes at 3 months, it was observed that 53% of patients with a FT
experienced a decrease of 10 points or more, while 45% of those without a FT experienced this
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same change. At 6 months post-treatment, 43% of FT patients had a decrease of at least 10
points, while this change was observed for 44% of patients in the NFT group. Finally, after 12
months, 29% of patients who received a FT during treatment had a clinically significant
decrease in MDADI-composite scores, compared to the 33% of patients without a FT who were
found to have this same decrease. Additionally, 12% of patients with a FT reported a clinically
significant increase in MDADI-composite score at 3 months, while only 2% of patients with a FT
were found to have increased their score by 10 or more points. When examining this change at
6 months, 19% of patients in the FT group experienced a 10 point increase, with only 7%
experiencing this change in the NFT group. At 12 months post-treatment, 18% of patients with
a FT were able to increase their composite MDADI score by 10 or more points, with 8% of
patients without a FT were recorded as having this increase.

Figure 2. Distribution of MDADI-Composite Scores According to Feeding Tube Status.
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Weight. There was no significant difference observed between the two groups with
respect to weight at any time point other than baseline (see ‘Baseline Patient and Treatment
Characteristics’). When analyzing within group differences, both the FT group (p = <.001) and
the NFT group (p = <.001) produced significant results. Further post-hoc testing revealed
baseline weight to be significantly higher than weight at 3 months (p = .001) and at 6 months (p
= <.001) for patients in the FT group. As for the NFT group, baseline weight was found to be
significantly higher compared to weight at 3 months (p < .001), 6 months (p < .001), and 1 year
(p < .001) post-treatment (Figure 5).
Clinically significant decreases in weight (≥10%) from baseline were also observed for
both groups (Figures 6 and 7). Overall, the percentage of patients who had a clinically
significant decrease in weight from baseline was higher for the NFT group at every point in
time. At 3 months, the FT group had 30% of patients lose more than 10% body weight, whereas
the NFT group had 50% of patients lose this clinically significant amount of weight. At 6 months
post-treatment (compared to baseline), 23% of patients with a FT had lost more than 10% of
their body weight, compared to 44% of patients without a FT. Finally, at 12 months posttreatment (also compared to baseline), only 13% of patients with FTs were still at a 10% deficit
in relation to baseline weight, compared to 40% of patients in the NFT group (Figure 6). In
terms of patients gaining a clinically significant amount of weight, only patients in the FT group
were documented to have gained more than 10% of their baseline weight at 3 (5%), 6 (5%), and
12 months (7%) after the completion of treatment. The NFT group showed no clinically
significant increases in weight at any time point of interest (Figure 6). Between-group and
within-group results are summarized below (Tables 4-6).

Figure 5. Distribution of Weight According to Feeding Tube Status.
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Table 4
Between-Group Comparison at Four Time Points (FT vs. No FT)
Outcome Measure

Baseline

3 Months

6 Months

12 Months

4.70
5.76*

5.14
6.00*

6.00
5.98

FOIS
FT 6.06
NFT 6.41
PSS-HN (Diet)
FT 78.9
57.0
62.5
78.6
NFT 82.0
66.5
70.9
76.3
MDADI (Functional)
FT 87.1
70.5
80.0
86.0
NFT 90.0
78.6
81.3
88.1
MDADI (Composite)
FT 83.2
67.8
73.3
79.5
NFT 88.1
75.8*
79.6
83.0
Weight (Kg)
FT 74.3
71.4
66.7
71.0
NFT 85.7*
74.8
74.9
76.0
Alpha = 0.05 (2-tailed)
* denotes significant p value
FOIS analysis utilized MWU/Wilcoxon Rank Sum; all other analyses utilized independent
samples t-test
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Table 5
Repeated Measures Analysis Summary
Outcome Measure

Baseline

3 Months

6 Months

12 Months

p value

4.70
5.76

5.14
6.00

6.00
5.98

.012*

FOIS
FT 6.06
NFT 6.41

.005*

PSS-HN (Diet)
.169
FT 78.9
57.0
62.5
78.6
.061
NFT 82.0
66.5
70.9
76.3
MDADI (Functional)
.548
FT 87.1
70.5
80.0
86.0
.020*
NFT 90.0
78.6
81.3
88.1
MDADI (Composite)
.179
FT 83.2
67.8
73.3
79.5
<.001*
NFT 88.1
75.8
79.6
83.0
Weight (Kg)
<.001*
FT 74.3
71.4
66.7
71.0
<.001*
NFT 85.7
74.8
74.9
76.0
Alpha = 0.05 (2-tailed)
* denotes significant p value
FOIS analysis utilized the Skillings-Mack Test; all other analyses utilized Linear Mixed Effects

66

Table 6
Post-Hoc Analysis Summary for Significant ANOVA’s
Variable
FOIS
(Wilcoxon Signed
Rank Test)

Patient Group
FT

No FT

Weight
(Satterthwaite)

FT

No FT

MDADI (Functional)
(Satterthwaite)

No FT

MDADI (Composite)
(Satterthwaite)

No FT

Alpha = 0.0083 (Bonferroni Correction)
* denotes significant p value

Time Points Compared
Baseline v. 3 Months
Baseline v. 6 Months
Baseline v. 12 Months
3 Months v. 6 Months
3 Months v. 12 Months
6 Months v. 12 Months
Baseline v. 3 Months
Baseline v. 6 Months
Baseline v. 12 Months
3 Months v. 6 Months
3 Months v. 12 Months
6 Months v. 12 Months
Baseline v. 3 Months
Baseline v. 6 Months
Baseline v. 12 Months
3 Months v. 6 Months
3 Months v. 12 Months
6 Months v. 12 Months
Baseline v. 3 Months
Baseline v. 6 Months
Baseline v. 12 Months
3 Months v. 6 Months
3 Months v. 12 Months
6 Months v. 12 Months
Baseline v. 3 Months
Baseline v. 6 Months
Baseline v. 12 Months
3 Months v. 6 Months
3 Months v. 12 Months
6 Months v. 12 Months
Baseline v. 3 Months
Baseline v. 6 Months
Baseline v. 12 Months
3 Months v. 6 Months
3 Months v. 12 Months
6 Months v. 12 Months

Significance (p value)
<.001*
.007*
.245
.489
.039
.111
<.001*
.007*
.001*
.096
.127
.986
.001*
<.001*
.035
.993
.914
.901
<.001*
<.001*
<.001*
.969
.528
.336
<.001*
<.001*
.226
.791
.010
.144
<.001*
<.001*
.009
.631
.043
.484
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Chapter 4: Discussion
Individuals diagnosed with OPSCC are likely to experience treatment-induced complications
which may ultimately affect their ability to meet nutritional demands. Thus, the ability to
promptly decide whether enteral feeding will be necessary is important to prevent
deterioration of nutrition and health. The capacity of physicians to communicate prognostic
expectations based on FT status has the potential to considerably improve treatment for
nutritionally compromised OPSCC patients. While it is well understood that many individuals
with HNC would benefit from nutritional support during their treatment, the optimal timing of
FT insertion may be extremely difficult to determine. Moreover, a widely-adopted,
standardized protocol to guide decision making regarding the timing of FT insertion is currently
lacking. Recalling Kramer et al. (2014), “considering patients’ disease characteristics and
baseline feeding capacity is an essential component for future research attempting to
contribute to the development of a protocol”. Therefore, comparing outcome measures related
to oral intake, dysphagia, and QoL has the potential to highlight key differences between those
who are given a FT and those who are not. This may in turn contribute to the establishment of
an evidence-based protocol, guiding tube placement and improving health outcomes for HNC
patients.
This study investigated differences in outcomes related to oral intake between individuals
diagnosed with oropharyngeal cancer who received an enteral FT during treatment versus
those who did not. Attention was focused on comparing specific outcome variables at four
treatment time points: at baseline (pre-treatment), and then at 3, 6, and 12 months posttreatment. Given these time points, inquiry was made into how the FOIS, PSS-HN (Normalcy of
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Diet subscale), MDADI-Composite and Functional scales), and weight changed over time for
each group in order to describe differences in trajectory of recovery. By exploring how the
outcome variables differed between the two groups – FT (FT) and no FT (NFT) at baseline, this
study also sought to determine pre-treatment differences that may in part have been
responsible for the placement of a FT. From these data, a secondary objective of this
investigation was directed toward determining potential predictive factors associated with
dependence on use of enteral FTs. Outcome variables were collected and then used to address
the following objectives:
1) To determine if baseline characteristics predict FT use and dependence for
individuals diagnosed with oropharyngeal cancer which was treated with IMRT;
2) Investigate the impact of FT status on long-term swallowing-related outcomes,
weight loss and QoL; and
3) Describe differences in the trajectory of recovery for outcome measures based on FT
use.
The discussion to follow will first address which baseline characteristics were likely to
predict FT use and dependence for this population. FT dependence will then be discussed in
terms of which outcome variable(s) was/were most useful in predicting duration of FT use, as
well as the magnitude of their effect. Next, key differences in outcomes at three post-treatment
time points will be addressed. This will include between-group comparisons of the FOIS, PSS-HN
(Normalcy of Diet), MDADI (functional and composite scales), and weight/weight change at 3, 6,
and 12 months post-treatment. This will be followed by of how each of the aforementioned
variables changed over time for each group, specifically addressing recovery and if their status
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returned to baseline levels. Finally, the clinical implications of the present data will be
presented, along with limitations and directions for future research.
Feeding Tube Placement
Patient characteristics. Based on patient/disease characteristics at baseline, no
differences between the two groups were found to exist (Table 1), with the exception of
weight. Other studies have shown a significantly increased risk of FT placement in patients who
had a higher T and N stage (T3/T4 and N ≥2) disease (Bhayani et al., 2012; Mays et al., 2014;
Yang et al., 2016). Additionally, factors such as sex have also been shown to be predictive of
enteral feeding, with males having a higher incidence of FT placement compared to females
(Wermker et al., 2012), making the present findings somewhat unexpected. The lack of a
difference could have been due to the highly selective approach taken to ensure a
homogeneous sample of participants. Many confounding factors that may have contributed to
FT use were removed though the inclusion criteria (e.g., disease site, IMRT vs. 3D conformal RT,
no surgery, etc.), leaving only outcome measures to potentially influence FT placement.
The findings from this study indicate that the FOIS, PSS-HN (Normalcy of Diet), and both
the functional and composite MDADI scores did not differ significantly between the FT and NFT
patient groups at baseline (see Table 2). Since individuals in the NFT group are able to tolerate
an oral diet without the need for enteral feeding, it would be expected that they would perform
significantly better at baseline, however, this was not the case. While baseline scores may not
fully represent a patient’s health considering they have yet to be exposed to the toxic effects of
treatment, the literature indicates that baseline measures of swallowing may be useful for
predicting who receives a FT and who does not (Bhayani et al., 2014; Yang 2016). While the NFT
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patient group did outperform the FT group over time in terms of the above-noted outcome
measures (Table 4), the lack of significant differences between groups indicates that those who
receive a FT during treatment are not much different than those who no not. These data
suggest that the ability to predict FT use and the decision to administer a FT may not be made
simply based on pre-treatment differences in FOIS, PSS-HN, and MDADI scores.
Pre-treatment oral function. While using the FOIS as a marker of oral intake presents
unique challenges, the measure does provide insight into the ability of patients to sustain oral
consumption of foods. Considering that no difference was found at baseline between the two
groups, a patient’s oral intake seems to be more affected by treatment rather than pretreatment issues. However, these findings conflict to some extent with established literature;
for example, Quon et al. (2015) found that those who did not require a FT had less pretreatment dysphagia and weight loss. Although these issues do not objectively represent oral
intake, they may be indicative of difficulty with eating/drinking even before treatment began.
A possible explanation for the lack of pre-treatment differences in oral intake could lie
in the weakness of the FOIS as an outcome measure. This cohort of patients did not undergo
prophylactic FT placement, and thus, all scored at the upper end of the FOIS (i.e., scores ranging
from 4 to 7) at baseline, since scores at the lower end of the FOIS (i.e., 1 to 3) inherently imply
the presence of a FT. However, once treatment began and many patients required a FT, those
who were provided enteral feeding then received FOIS scores that are distinctive from those in
the NFT group. Therefore, it seems that oral intake as measured by the FOIS may be used to as
a prognostic marker after the commencement of treatment, rather than as a predictive variable
at baseline to decide whether or not a patient will require a FT.
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Pre-treatment weight. The overwhelming consensus in the field of HNC rehabilitation is
that limiting weight loss is crucial for progressing through treatment with minimal interruptions
(Bhayani et al., 2013; Shaw et al., 2015; Laguis et al., 2016). While decreases in weight (≥10%)
have been demonstrated to have clinically meaningful implications, associations between
weight at baseline and tube status have yet to be thoroughly investigated. The current findings
may be used to distinguish between patients who will need a tube and those who will be able
to orally consume their nutrition before treatment begins.
In the direct comparison of FT and NFT patients at baseline, weight was the only
variable that emerged as being significantly different (Table 4). This finding is consistent with
current literature on tube status and weight loss; Quon et al. (2015) also showed that patients
who did not require a FT had less pre-treatment weight loss. Because the NFT group had a
significantly higher mean baseline weight, meaningful conclusions can be suggested. First,
despite the absence of other significant between-group differences at baseline (e.g., disease
characteristics, FOIS score, etc.), the findings appear to indicate that there may be a common
variable among patients in the FT group that affects maintenance of one’s pre-treatment
weight compared to their NFT counterparts. Furthermore, baseline differences in weight
suggest the need for specific weight loss screening alongside the use of other function-related
outcome measures used. Perhaps the most valuable finding is that while weight has been
confirmed to be an important pre-treatment indicator of FT use/placement, none of the
variables assessed in this study have the ability to represent the lower average weight at
baseline for patients with a FT. Additionally, they cannot be used to predict post-treatment FT
placement.
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Feeding Tube Duration
Because there is evidence to suggest that FT use can lead to an increased likelihood of
long-term dependence, especially for those with pre-existing dysphagia and weight loss
(Bhayani et al., 2013; Jang et al., 2013; Verma et al., 2015), this study sought to examine
variables that may have predicted duration of FT use in this patient population. The strongest
predictor of FT duration was the combination of the FOIS, PSS-HN (Normalcy of Diet), the two
MDADI scales (functional and composite), and weight. Although the R2 value was quite high for
this combination of variables (Table 2), the true significance of this analysis is unknown given
the small number of data points available (n = 9). Further, these variables were far better at
predicting FT duration when values at 3 months were used compared to baseline scores. The
largest R2 value for baseline prediction was less than almost every value at 3 months, indicating
that the 3 month time point should be used to determine whether or not patients will require a
FT.
The decision to leave a FT in place is complex and multidimensional, relying on many
factors outside of objective patient characteristics. Other factors (e.g., the absence of
family/friends to help with feeding, variations in lifestyle, the presence of unrelated
comorbidities, etc.) are not represented in the outcomes used and may contribute to extended
FT use. The presence of confounding variables may help to explain variance not captured by
statistical analysis. Therefore, this finding should not be interpreted to suggest that the
measures included in this study alone are the only variables that may be useful in predicting FT
duration/dependence, especially at 3 months post-treatment.
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Feeding Tube Status
Functional oral intake. The current body of literature on the use of the FOIS as a
marker of oral intake and/or oral dietary tolerance is extensive (Kotz et al., 2012; CarnabyMann et al., 2012; Messing et al., 2017; Ringash et al., 2017). The FOIS enabled objective
characterization of oral dietary intake on a scale of one through seven, allowing for direct
comparisons between the groups. While numerous measurement tools that allow for
documentation of oral intake of food and liquids are available, many also measure additional
aspects of impairment, and are commonly disease-specific (List, Ritter-Sterr, & Lansky, 1990;
Hillel et al., 1989). The FOIS was chosen as a primary outcome measure in the present study
because of its singular focus on documenting mode of nutritional intake.
Of equal importance in selecting a primary outcome measure is consideration of the
psychometric of the measure. Inter-rater reliability for the FOIS was initially established by 6
experienced Speech-Language Pathologists (S-LPs; Crary et al., 2005). Despite the fact that no
training was provided to raters (other than a simple description of the scale), agreement
between paired judges ranged from 85%-95% (Crary et al., 2005). This finding demonstrates the
robust nature of the FOIS and supports use without additional training by clinicians specializing
in the treatment of dysphagia.
Moreover, the FOIS also showed high consensual validity, with the raters often agreeing
(81%-98%) with the scale ratings as predefined by the authors (Crary et al., 2005). This finding
reflects exceptional agreement with the progression of items across the seven FOIS levels,
supporting the present use of this scale to monitor changes in oral intake. Finally, because the
FOIS provides information regarding the special preparations or limitations patients make in
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their diet, as well as the necessity for supplementation with a FT, it is ideal to use when
assessing how much of one’s diet is consumed orally, especially with a FT.
However, despite the frequent use and application of the FOIS, little is known regarding
how scores differ between those with a FT and those without, and how this affects the
trajectory of recovery for each unique group. Research emphasizes the importance of
maintaining oral intake – regardless of tube status – to prevent muscle wasting and remodelling
of musculature (Kasper et al., 2002; Clark, 2009; Hutcheson et al., 2013). Investigating such
differences is critical to establish and communicate realistic treatment goals, as well as to the
development of a standardized protocol based on patient characteristics and FT status.
In the current study, patients in the FT group had significantly lower FOIS scores at 3 and
6 months post-treatment when compared to the NFT group, despite no statistical difference
being found at baseline and 12 months (Table 4). As expected, those without a FT are generally
able to tolerate a fully oral diet, thus, their oral intake as represented by the FOIS should indeed
be higher. It is noteworthy to understand that patients in the FT group did not approximate
baseline oral intake until 12 months post-treatment. The findings of this study provide
information on the oral intake of patients with and without FTs as they progress through
treatment.
Within-group analyses revealed that both the FT and NFT groups demonstrated altered
oral intake at 3 and 6 months compared to baseline (see Table 6). This indicates that both
patient groups may be at risk for negative health outcomes associated with a nutritionally
compromised status during this time frame. Interestingly, the trajectory of altered oral intake
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differed between the groups. Specific inquiry into where these differences emerged yielded
interesting results.
For individuals in the FT group, a significant difference was found when comparing FOIS
scores at baseline and 3 months, as well as between baseline and 6 months. Similarly,
individuals in the NFT group also exhibited a significant difference between scores at baseline
and 3 months, and baseline and 6 months. While these results indicate a drop in functional oral
intake, independent of tube status, a key difference in the trend of recovery was evident. For
NFT patients, there was also a significant difference between baseline and 12 months (Table 6).
Because FOIS scores for NFT individuals were higher at baseline compared to 12 months, and
because the difference was statistically significant, it is fair to conclude that the functional oral
intake of this group did not return to baseline levels even after 12 months. This trend is
inherently different from the return to baseline levels noted at 12 months post-treatment for
the FT group. Interpreting this difference between the groups is challenging in the context of a
retrospective study. In future investigations, it would be interesting to examine if significant
change in FOIS scores at 3 months, or even at an intervening time point after the start of
treatment, might prove to be a useful indicator of need for nutritional support.
Normalcy of diet. To complement the FOIS, and to provide an idea of the patients’
ability to tolerate a range of foods by mouth, between-group comparisons were also conducted
using the PSS-HN (Normalcy of Diet) subscale. The present finding of no significant differences
between groups relative to Normalcy of Diet ratings was surprising. Considering the variation in
FOIS scores over time for both groups, and the fact that a large proportion (32%) of patients
received FTs (Table 1), the degree to which patients were able to tolerate a range of foods by
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mouth was expected to diminish after treatment. Although current literature using the PSS-HN
as an outcome measure reports no relation between the scale and gastrostomy tube placement
(Morton, Crowder, Mawdsley, Ong, & Izzard, 2008), differences were nonetheless expected
considering that individuals with a FT are expected to have an abnormal/altered diet.
Based on findings by Quon et al. (2015), the lack of significant change in PSS-HN
Normalcy of Diet scores across time is also unexpected. Quon et al (2015) found that all three
groups of patients (prophylactic, reactive, and no FT) showed a similar trend in post-treatment
scores, demonstrating a decline in the number of patients without dietary restrictions, as well
as an increase in patients limited to foods of softer consistency. In contrast, the present study
found no such change over time. One possible explanation for the contrasting results is that
Quon et al. (2015) included patients from 2004-2007, when 3D-conformal radiation therapy
was still commonly being used to treat HNC. Thus, differences in the sample populations and
treatment modality could have contributed to the contradictory findings.
Dysphagia and QoL. Established literature makes it clear that dysphagia is a common
and serious issue in those treated for OPSCC (Langendijk et al., 2008; Nguyen et al., 2005;
Nguyen et al., 2006), leading to significant alterations in QoL (Manoor et al., 2012). To better
understand the impact of OPSCC treatment on swallow function and swallowing-related QOL,
scores from the functional and composite subscales of the MDADI were collected. To fully
understand the impact of altered oral intake on one’s health, it is of great value to investigate
swallowing-related QoL. Consisting of four subscales addressing the global, emotional,
functional and physical impact of dysphagia on QoL, the MDADI allows for a comprehensive
analysis of how patients are affected by treatment.
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The MDADI must have psychometrical rigour, and strong reliability and validity in order
to be utilized as an outcome measure. Each MDADI subscale has demonstrated acceptable
internal consistency and test-retest reliability (Chen et al., 2001). The criterion validity of the
MDADI was determined in comparison to the Performance Status Scale-Head and Neck (PSSHN), an instrument considered as a gold standard measurement tool with respect to oral intake
and swallowing function. Within the global, emotional, and physical subscales of the MDADI,
criterion validity ranges from moderate to moderately-high (Chen et al., 2001).
MDADI data were used to supplement information obtained from the PSS and FOIS.
Because it allows for inquiry into how dysphagia affects a patient’s psychosocial and emotional
well-being, the scale provides a more complete analysis of the effects of HNC treatment.
Finally, the assumption can be made that the longer the interval between the end of treatment
and MDADI assessment, the higher the scores should be. In theory, if a patient has been posttreatment for a long period, they have had more time to adapt to the deficits caused by the
tumour and/or or treatment itself. Taking this into account, Chen et al. (2001) found that the
longer the time interval between the end of treatment and MDADI assessment, the higher the
global MDADI score, reflecting higher QoL scores and a higher level of swallowing functionality.
Together, the composite and functional MDADI scales assess QoL in relation to difficulty
with swallowing. In this study, data from the functional subscale failed to reveal significant
differences between the FT and NFT groups. However, individuals without a FT still experienced
higher/better overall scores at each point in time (Table 4). This may be a trend that simply
requires a larger sample size to become statistically significant. Although a patient-reported
measure, the functional subscale has been shown to be reflective of swallowing function in the
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absence of objective, direct examination (Hutcheson et al., 2017). Based on the present
findings, it is reasonable to suggest that these groups did not differ relative to swallowing
function. This might indicate that patients in the FT group did not receive enteral feeding
because of swallowing function, but other variables (e.g., odynophagia).
The composite subscale, a score summarizing overall performance as a weighted
average of the physical, emotional, and functional subscale scores, provides a more holistic
view of the impact of swallowing impairment on QoL (Hutcheson et al., 2017). With respect to
the composite MDADI subscale, a statistically significant difference was identified between
groups at 3 months post-treatment. This finding suggests that a FT is associated with lower
perceived swallowing-related QoL at 3 months post-treatment. The benefit that comes from
knowing about changes in QoL over time, and in particular, the significant difference between
the groups at 3 months, is that the information can help health care professionals provide more
accurate counselling and education to patients. This will allow the professionals to be attuned
to this anticipated change in QoL.
Neither the functional or composite MDADI scores changed significantly over time for
individuals who received a FT. One study that investigated factors predicting two-year
composite MDADI outcomes for oropharyngeal cancer patients reported a significant reduction
in scores at 6 months post-treatment when compared to baseline (Goepfert et al., 2017). Even
though participants in the Goepfert et al. (2017) study were not grouped according to FT status,
the finding suggests that a decline in MDADI scores should still be expected within this
population. In contrast, statistically significant changes were observed over time for both the
functional and composite MDADI scores in the NFT group. These findings suggest that the NFT
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group had a more difficult time, relative to their baseline standing, at 3 and 6 months after their
treatment concluded.
The utility of administering the composite MDADI scale has been enhanced by the
identification that fluctuation of ≥10 points is indicative of clinically significant differences
(Hutcheson et al., 2016; Goff et al., 2017) Upon examining the percentage of patients with this
clinically relevant decrease in composite MDADI scores, a higher proportion of patients in the
FT group were found to have this decline at 3 months post-treatment (Figure 6). However, over
time, the percentage of FT patients demonstrating a clinically significant decline in their scores
decreased, and by 12 months, a much smaller percentage of those in the FT group exhibited
this decrease compared to the NFT group (Figure 6). Perhaps the most interesting discovery in
regard to composite MDADI scores is that a far higher percentage of patients in the FT group
had a ≥10 point increase in their score at every assessment time. The FT group outperformed
the NFT group, with the NFT group demonstrating a more protracted course of improvements
in swallowing-related QoL. These findings indicate that the two groups differ in their baseline
QoL, and their trajectory of recovery, a finding which may be useful information to provide to
patients ahead of treatment. FTs are indicated to improve nutritional outcomes, but they may
have unintended consequences for QoL – patients who know this prior to treatment may be
less apt to have large declines in QoL.
A potential explanation as to why dysphagia may not have a significant effect on the
daily activities of FT individuals (i.e., functional MDADI scores) is that they may attribute these
difficulties to the FT itself. Patients with a FT are more likely to eat alone (Quon et al., 2015),
thus, may be restricted and may not participate in many of their regular daily activities.
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Additionally, because the MDADI is reported by the patient themselves, objective changes in
swallowing function may not necessarily be represented. How the patient perceives their
swallowing function may be different than compared to objective, quantifiable changes.
Nonetheless, the fact that these individuals required enteral feeding suggests that they could
have had some clinically relevant drop in swallowing function, which functional MDADI scores
were unable to detect.
Weight. The prevention of weight loss is an established marker of successful HNC
treatment, leading to less treatment-related toxicity and complications (Languis et al., 2016;
Shaw et al., 2015; Bhayani et al., 2013). The efficacy of reactive FT placement for the prevention
of weight loss is highlighted by the lack of statistically significant differences between the two
groups at all post-treatment time points. Despite those in the NFT group having a higher mean
weight at every point of assessment (Table 4), a significant difference was only found at
baseline between the two groups. The findings corroborate the current stance on weight loss
prior to treatment, in that patients without a FT are more likely to have less pre-treatment
weight loss (Quon et al., 2015). Thus, it may be inferred that significant differences in mean
weight after treatment are not solely dependent on FT status. One explanation is that raw
weight may not be the most appropriate metric to compare long-term outcomes, since many
factors outside of FT status can influence one’s weight.
Although there was no statistical difference in mean weight post-treatment, the
percentage of individuals losing ≥10% of their baseline weight was higher in the NFT group,
especially at 12 months (Figure 6). It was expected that by 12 months, patients not requiring
enteral feeding – and in turn were able to consume their nutrition orally – would not have such
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a high proportion of individuals (16/40, 40%) with a clinically significant decline in weight.
Further, when investigating the percentage of patients with a clinically significant increase in
weight, no patients in the NFT group showed any such improvement (Figure 7). In contrast, a
notable number of FT patients did increase their weight by 10% at each time point. This finding
leads to two possible conclusions: (1) reactive FT placement served the intended purpose of
maintaining weight in patients otherwise at risk, and (2) those who did not receive a FT went on
to experience significant decreases in weight with greater frequency than those with tube
feeding. Weight loss negatively affects prognosis and leads to reduce survival outcomes in HNC
(Languis et al., 2013). Therefore, not only should weight or weight change at baseline be a
consideration for nutrition management, but ongoing monitoring may identify patients who
experience clinically significant weight loss later in treatment, who may also benefit from
nutritional monitoring and support (Lynch, 2017).
Despite the mean weight of NFT patients being consistently higher, it is interesting to
note that their mean weight did not return to pre-treatment levels at 12 months (Table 5).
Results indicated that for those without a FT, weight at 12 months was significantly lower than
at baseline. On the contrary, the patients with a FT exhibited no significant difference,
indicating recovery back to their baseline weight. Since their initial weight was lower, a return
to baseline may have been easier for the FT group. Still, this finding indicates that although
baseline weight may be utilized to predict tube placement, it does not predict long-term (12
month) prognosis. Furthermore, a significant difference was observed for both groups between
baseline and 3 months, and baseline and 6 months, indicating that mean weight decreased
significantly from baseline at these two points in time. The trajectory of recovery for both
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groups, with respect to all outcome variables of interest used in this investigation, seems to
follow this trend.
Clinical Implications
Based on the three primary objectives, this study highlights important differences in
outcomes related to health, swallowing, and QoL for those with OPSCC grouped according to FT
status. Several components of the results obtained may be of value from a clinical decisionmaking perspective. When using outcome variable data to determine if differences exist based
on FT status, it is important to first determine the time point at which this difference exists and
whether individuals recover back to baseline status. If differences are commonly identified at a
specific time, and if these differences seem to affect recovery in the long term, then the
variables in question can be used to provide more specific treatment recommendations based
on treatment and patient characteristics.
Patients utilizing enteral feeding during treatment differ in relation to health outcomes
and recovery when compared to those who are able to consume a fully oral diet. These
differences most often manifest at 3 months post-treatment, with outcomes representing
maintained oral intake and difficulty with swallowing being significantly better for those
without a FT. As a result, consideration at this point in time (or even prior to 3 months) by
clinicians should be undertaken to determine whether or not treatment will necessitate the use
of enteral feeding.
Within this setting and for this population, the absence of statistically significant
differences between the two groups at 12 months could indicate that current clinical practice is
meeting patient needs. No outcome variables were found to significantly differ at this time,
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implying that reactive FTs were appropriately selected for those at-risk. There was, however, a
concerning inability for patients without a FT to return to their baseline weight and oral intake
level. This finding suggests that some patients without a FT may have benefited from enteral
feeding. A more detailed investigation into the characteristics of specific patients without a FT
which may have led to a decline in long-term outcomes would offer valuable information for
guiding standard clinical practice. After this type of information is collected, factors responsible
for long-term deficits could emerge and be utilized in the decision-making process for
gastrostomy tube insertion.
This investigation also addressed how specific outcome variables correlate with the
length of tube insertion in order to determine which have the greatest impact on prolonging
tube use. Since dependence on enteral feeding has been associated with issues such as the
development of esophageal toxicity and dysphagia (Bhayani et al., 2013), identifying those
variables which have the strongest correlation with duration of tube insertion may provide
valuable information. Health care professionals will be able to focus on and allocate resources
towards improving the variables they know will have the greatest positive impact.
The benefits of maintaining oral intake throughout treatment have been described, with
Hutcheson et al. (2013) conducting an investigation to assess the effects of maintained oral
intake and adherence to swallowing exercises on long-term outcomes. The present
investigation built onto the knowledge generated from studies such as the Hutcheson paper,
with variations in the methodology used. Hutcheson et al. (2013) investigated maintained oral
intake using only three categories: (1) nothing by mouth (fully gastrostomy tube dependent) (2)

84

partial oral intake (tube feeding supplemented by consistent daily oral intake) and (3) full oral
intake (100% diet consumed orally).
By using the FOIS and PSS-Diet scales to determine the level of maintained oral intake
throughout treatment, this present research has provided more specific information regarding
the amount of oral intake that accompanies FT use in this patient population. Hutcheson et al.
(2013) used two main swallowing-related outcome measures to test the effect of maintained
oral intake, diet level and length of FT dependence. However, little emphasis has been placed
on determining what level of maintained oral intake is directly associated with actual
swallowing functionality, and how this relates to other variables such as weight loss during
treatment. Future investigations investigate questions relating to the maintenance of oral
intake in terms of the ratio of oral to enteral feeding, providing more specific numbers unable
to currently be obtained by using any validated scale. Furthermore, the diversity of patient
characteristics and treatment variables seen in the Hutcheson et al. (2013) investigation were
controlled for in this study, since all patients had oropharyngeal cancer and were treated with
either concurrent CRT or RT alone, using IMRT as the only RT technique.
By knowing how health-related outcomes impact FT dependence and which have the
greatest effect, physicians can direct their focus and attention to improving issues they know
will make the greatest impact on their patient’s health and well-being. The present study found
that data from all outcome measures at 3 months correlated more strongly with length of tube
duration than did data from baseline. Since patients with OPSCC are living longer posttreatment, minimizing the associated toxicities of treatment and decreasing the risk of FT
dependency is essential. The increased survival of this population would be less meaningful if
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treatment and reliance on enteral feeding led to a long-term decrease in QoL. Therefore,
clinicians may wish to identify patents at a high risk for FT dependence using assessment at 3
months post-treatment.
Limitations and Directions for Future Research
Documenting oral intake. Shaw et al. (2015, p. 170) noted that, “…ideally, future
studies would measure the proportion of oral vs. enteral intake to determine the impact of
continued swallowing during RT on long-term swallowing-related outcomes”. The retrospective
nature of the present investigation is limiting in that this information was unavailable. While
the FOIS does possess several distinct advantages, a key limitation must be addressed in future
work if it is to be used as an outcome measure comparing patients based on FT status. That is,
because the scale is ultimately divided into two categories, it may depict biased results in
attempting to measure oral intake in patients without a FT.
Levels one to three of the FOIS imply that a FT is in place and oral intake is judged
accordingly. This presents a significant concern with attempting to compare groups of patients
based on whether or not they have a FT inserted. For example, if there is no FT, the patient
must receive a score of 4 or greater. On the other hand, if a patient does have a FT, they are
likely to be given a score between 1 and 3. Thus, only individuals with a FT are able to score in
the lower end of the scale (1 to 3), making their average FOIS score seem lower even if a similar
level of oral intake is observed compared to NFT individuals. To reduce this limitation, future
prospective research should aim to objectively capture the full functional oral intake of
participants by calculating the percent/ratio of oral intake to enteral intake, and using the
calculated percentage instead of the FOIS in statistical analyses comparing levels of oral intake.
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Missing data. As is commonly the case with retrospective chart reviews, outcome
measure data was missing at several points in time. Although data was available for some
patients at all four time points, the remainder of the sample provided data at one, two or three
points in time. This led to an unequal distribution of sample size (n) at every time point,
complicating the repeated measures analysis for objective three (trajectory of recovery). Within
a data set, “missingness” may be grouped according to whether the data are “missing
completely at random”, “missing at random”, and “missing not at random” (Sterne et al., 2009).
The missing data within this investigation can be described as “missing completely at random”,
since the missing observations are a random subset of all observations (Bhaskaran & Smeeth,
2014). It is likely that the observed values and the missing values will have similar distributions
due in part to the multiple variable reasons why data were missing in the first place. Often, if
patients became extremely ill, instrument-driven data collection ceased and became more
descriptive as focus was directed increasingly towards palliative care and symptom
management. Also, inherent logistical challenges in scheduling a multitude of patient follow-up
appointments at each time point may have impacted the completeness of the dataset. As a
result, there may have been no systematic difference the missing and observed outcome
measures, allowing the data to be used an unbiased and statistically valid manner. To
effectively handle the missing-at-random data, the appropriate selection of statistical analyses
was required. Several tests capable of incorporating large data sets with missing variables were
used, allowing for the production of statistically sound results.
It is unfair to suggest that a specific methodology could be utilized in future research to
ensure that all variables are collected at every point in time. Work with oncology populations
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does carry real risk relative to data collection, seeing as a wide variety of issues could arise,
ultimately limiting complete collection of data (e.g., patients foregoing curative treatment and
instead pursuing palliative care, asymptomatic patients not requiring consistent
care/assessment, high case load demands for health care professionals, etc.). Researchers
interested in conducting a more data-rich investigation should ensure that variables of interest
are prospectively collected. Additionally, health care professionals responsible for collecting
research data should be supported in prioritizing patient assessment and the recording of
assessment results when appropriate to ensure a complete data set is obtained.
Methodology. As a consequence of retrospective data collection, the option of
randomizing patients to groups based on FT status was not possible. To some extent, this may
have resulted in differences in baseline/pre-treatment characteristics between the two groups.
As a result, it is likely that patients with more baseline weight loss, and/or worse overall healthstatus were chosen to undergo reactive FT placement. Moreover, although FT status was the
independent variable for almost every comparison, the exact timing of placement was not as an
indicator of tube status.
Randomizing patients into groups, and taking into account timing of insertion would
ensure that individuals in the FT group actually have a tube inserted at the time of comparison.
In addition, collecting outcome variable data immediately after the completion of RT/CRT
would be worthwhile. The 3-month time point appears to most often be associated with
significant differences based on FT status. Therefore, it would be valuable to collect data at
some point between the end of treatment and 3 months. Identifying an earlier point in time
where the groups differ significantly may contribute to the development of a decision-guiding
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protocol which is able to identify nutritionally compromised patients much sooner, leading to
timely and effective gastrostomy tube placement.
Finally, the clinical literature has found proactive swallowing exercises to lead to better
swallowing-related QoL (Kulbersh et al., 2006; Shinn et al., 2013), lower rates of FT placement
(Bhayani et al., 2013), superior tongue and base and epiglotic movement (Caroll et al., 2008),
and shorter duration of PEG dependence (Bhayani et al., 2013). However, the present study
was unable to account for the amount of exercise that was prescribed to patients and this
factor may limit the external validity of these findings. Accordingly, future studies should
control or account for the prescription of swallowing exercise to investigate the impact of oral
intake in a more systematic manner.
Conclusions
Within the literature, there exists a need for a standardized protocol to guide optimal
timing of FT insertion for the HNC population. The present study investigated how health- and
QoL-related outcome variables are impacted by FT status, and if these variables are able to
predict FT placement. The findings indicated that such differences are most apparent at 3
months post-treatment, as patients without enteral feeding showed significantly better results
in outcomes related to oral intake and dysphagia. Clinically significant decreases in weight
stood out as the primary concern/difference amongst individuals without enteral feeding and
indicated difficulty with returning to baseline weight.
Differences in patient characteristics based on FT status may contribute to the
development of standardized protocol to determine optimal timing of FT placement. These
findings also have the potential to contribute to improved decision-making and communication
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in a clinical setting. Future research should focus on using prospectively collected outcome
measures to ensure they better represent the issues at hand (i.e., using the ratio of oral to
enteral feeding to represent continued oral intake). Given the key differences between FT and
NFT patients, and the potential differences which could emerge as a result of utilizing a much
larger sample size, the value of continuing such research is evident. Data of this type hold
substantial potential to improve communication with those who are undergoing treatment for
OPSCC and may ultimately lead to better outcomes.
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Appendices
Appendix A: List of Abbreviations
BMI
CRT
FOIS
FT
G-J
G-tube
HNC
HPV
IMRT
MDADI
NG
NFT
OPSCC
PEG
PSS-HN
QoL
RT
SCCHN
TORS

Body mass index
Concurrent chemoradiotherapy
Functional Oral Intake Scale
Feeding tube
Gastro-jejunostomy
Gastrostomy tube
Head and neck cancer
Human papillomavirus
Intensity modulated radiotherapy
M.D. Anderson Dysphagia Inventory
Nasogastric
No feeding tube
Oropharyngeal squamous cell carcinoma
Percutaneous endoscopic gastrostomy
Performance Status Scale for Head and Neck Cancer
Quality of life
Radiotherapy
Squamous cell carcinoma of the head and neck
Transoral robotic surgery
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Appendix B: Functional Oral Intake Scale (FOIS)
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Appendix C: Performance Status Scale for Head and Neck Cancer (PSS-HN)
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Appendix D: M.D. Anderson Dysphagia Inventory (MDADI)
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